webappendix
form
part
origin
submiss
peer
review
post
suppli
author
supplement
modjarrad
k
robert
cc
mill
kt
et
al
safeti
immunogen
antimiddl
east
respiratori
syndrom
coronaviru
dna
vaccin
phase
openlabel
singlearm
doseescal
trial
lancet
infect
di
publish
onlin
juli
http
dx
method
interpret
recombin
merscov
spike
glycoprotein
amino
acid
portion
sino
biolog
bound
solid
phase
microtit
plate
overnight
plate
wash
block
sequenti
incub
fourfold
serial
dilut
serum
particip
start
duplic
horseradish
peroxidas
enzymeconjug
antihuman
igg
secondari
reagent
peroxidas
substrat
mandel
scientif
ad
plate
optic
densiti
nm
measur
standard
micropl
reader
serum
merscov
infect
rhesu
macaqu
preclin
test
serv
posit
control
assay
endpoint
titer
antibodi
serum
defin
reciproc
highest
serum
dilut
measur
optic
densiti
greater
plate
cutoff
valu
posit
defin
endpoint
titer
neg
report
flselisa
except
plate
coat
recombin
fulllength
merscov
protein
sino
biolog
dilut
seri
particip
serum
fivefold
start
posit
defin
endpoint
titer
neg
report
particip
serum
serial
dilut
twofold
triplic
start
mix
plaqu
form
unit
merscov
strain
incub
allow
serum
antibodi
viru
interact
serumvirusmedium
mixtur
ad
monolay
vero
cell
follow
incub
light
microscopi
use
evalu
cytopath
effect
well
neutral
assay
defin
reduct
virusinduc
cytopath
effect
per
well
titer
valu
replic
defin
reciproc
highest
serum
dilut
reduct
cytopath
effect
observ
result
report
gmt
triplic
measur
posit
defin
endpoint
gmt
two
three
replic
posit
neg
report
one
three
replic
posit
replic
posit
human
elispotpro
kit
mabtech
use
direct
briefli
frozen
particip
pbmc
thaw
rest
overnight
plate
precoat
specif
captur
antibodi
wash
block
media
contain
fb
cell
stimul
hour
five
pool
custom
synthesi
genscript
pool
contain
peptid
peptid
overlap
amino
acid
span
entir
merscov
sglycoprotein
secret
detect
alkalin
phosphatas
conjug
antibodi
signal
develop
use
bcipnbtplu
substrat
spot
count
use
ctl
immunospot
plate
reader
softwar
spot
count
peptid
pool
calcul
backgroundsubtract
sfumillion
pbmc
total
sfumillion
pbmc
count
peptid
pool
report
posit
defin
sfumillion
pbmc
two
time
mean
total
spot
count
baselin
sampl
screen
laboratori
abnorm
greater
equal
grade
abl
will
compli
studi
procedur
screen
bmi
greater
equal
pi
decis
relat
ill
condit
may
interfer
studi
requir
activ
drug
alcohol
use
may
affect
studi
requir
week
week
week
week
week
week
week
week
nnumber
particip
mitt
popul
ncnot
calcul
lack
respons
across
group
pvalu
calcul
day
week
week
week
week
week
week
week
week
week
pvalu
nomin
prespecifi
infer
adjust
multipl
supplementari
appendix
safeti
immunogen
mer
dna
vaccin
page
acknowledg
read
protocol
agre
contain
necessari
detail
carri
studi
describ
understand
must
review
institut
review
board
independ
ethic
committe
overse
conduct
studi
receiv
approv
favor
opinion
implement
signatur
princip
investig
sponsor
medic
monitor
constitut
approv
protocol
provid
necessari
assur
studi
conduct
accord
declar
helsinki
gcp
ich
guidelin
local
legal
regulatori
regul
well
stipul
protocol
clinic
administr
section
includ
statement
regard
confidenti
research
hypothesi
administ
intramuscular
im
inject
follow
electropor
ep
welltoler
immunogen
phase
openlabel
dose
rang
studi
evalu
safeti
toler
immunogen
contain
plasmid
encod
consensu
sequenc
spike
protein
middl
eastern
respiratori
syndrom
coronaviru
mer
cov
current
approv
treatment
prophylact
vaccin
mer
cov
although
number
product
pois
advanc
human
trial
clinic
trial
evalu
whether
administ
via
intramuscular
im
inject
follow
ep
abl
gener
protect
immun
mer
cov
whether
immun
reactiv
follow
pattern
vaccin
dose
respons
inject
given
deltoid
later
quadricep
muscl
follow
immedi
ep
cellectra
devic
particip
per
group
administ
one
three
dose
level
mg
mg
mg
dnados
dose
administ
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
occur
week
week
schedul
estim
approxim
particip
need
screen
fill
desir
enrol
particip
v
assess
particip
monitor
advers
event
util
toxic
grade
scale
healthi
adult
adolesc
volunt
enrol
prevent
vaccin
clinic
trial
appendix
b
pain
assess
minimum
minut
post
vaccin
accord
ae
grade
scale
appendix
b
laboratori
safeti
assess
obtain
screen
week
follow
st
vaccin
week
follow
nd
rd
vaccin
advers
event
monitor
time
inform
consent
studi
discharg
telephon
day
post
vaccin
week
onsit
visit
week
month
final
vaccin
inject
site
reaction
monitor
approxim
month
follow
vaccin
event
stop
criterion
reach
section
studi
continu
full
discuss
conduct
dod
research
monitor
medic
monitor
princip
investig
irb
applic
immunogen
assess
blood
obtain
antibodi
tcell
respons
baselin
week
week
follow
vaccin
month
follow
final
vaccin
serum
separ
sent
analysi
humor
respons
neutral
bind
antibodi
titer
laboratori
dr
gari
kobing
nation
microbiolog
laboratori
quebec
canada
whole
blood
process
obtain
peripher
blood
mononuclear
cell
pbmc
determin
cell
mediat
immun
respons
tcell
respons
mer
cov
peptid
inclus
criteria
age
year
militari
civilian
male
femal
b
abl
provid
consent
particip
sign
inform
consent
form
icf
c
abl
will
compli
studi
procedur
women
childbear
potenti
agre
either
remain
sexual
abstin
use
medic
effect
contracept
oral
contracept
barrier
method
spermicid
etc
partner
steril
enrol
month
follow
last
inject
partner
unabl
induc
pregnanc
e
sexual
activ
men
consid
sexual
fertil
must
agre
use
either
barrier
method
contracept
studi
agre
continu
use
least
month
follow
last
inject
partner
perman
steril
unabl
becom
pregnant
inform
volunt
medic
histori
sexual
partner
base
selfreport
femal
volunt
current
pregnanc
statu
verifi
either
urin
serum
pregnanc
test
f
normal
screen
ecg
screen
ecg
clinic
signific
find
g
screen
laboratori
must
within
normal
limit
grade
find
appendix
b
h
histori
clinic
signific
immunosuppress
autoimmun
diseas
current
within
previou
week
take
immunosuppress
agent
exclud
inhal
topic
skin
andor
eye
dropcontain
corticosteroid
lowdos
methotrex
corticosteroid
dose
less
mgday
c
previou
infect
mer
cov
assess
self
report
solicit
exposur
histori
administr
vaccin
within
week
first
dose
e
bmi
greater
equal
f
administr
monoclon
polyclon
antibodi
product
within
week
first
dose
g
administr
blood
product
within
month
first
dose
h
pregnanc
breast
feed
plan
becom
pregnant
cours
studi
histori
posit
serolog
test
hiv
hepat
b
surfac
antigen
hbsag
potenti
communic
infecti
diseas
determin
princip
investig
medic
monitor
j
posit
serolog
test
hepat
c
except
success
treatment
confirm
sustain
virolog
respons
k
baselin
evid
kidney
diseas
measur
creatinin
greater
ckd
stage
ii
greater
l
baselin
screen
lab
grade
higher
abnorm
appendix
b
chronic
liver
diseas
cirrhosi
n
immunosuppress
ill
includ
hematolog
malign
histori
solid
organ
bone
marrow
transplant
current
anticip
concomit
immunosuppress
therapi
exclud
inhal
topic
skin
andor
eye
dropcontain
corticosteroid
lowdos
methotrex
corticosteroid
dose
less
mgday
p
current
anticip
treatment
inhibitor
eg
infliximab
adalimumab
etanercept
q
prior
major
surgeri
radiat
therapi
within
week
group
assign
r
preexcit
syndrom
eg
wolffparkinsonwhit
syndrom
presenc
cardiac
pacemak
automat
implant
cardiovert
defibril
aicd
metal
implant
within
cm
plan
site
inject
u
presenc
keloid
scar
format
hypertroph
scar
clinic
signific
medic
condit
plan
site
inject
v
prison
particip
compulsorili
detain
involuntari
incarcer
treatment
either
physic
psychiatr
ill
w
activ
drug
alcohol
use
depend
opinion
investig
would
interfer
adher
studi
requir
assess
immunolog
endpoint
introduct
particip
present
hospit
jeddah
saudi
arabia
progress
respiratori
ill
renal
failur
viral
cultur
yield
novel
coronaviru
zaki
nejm
subsequ
case
identifi
among
live
travel
saudi
arabia
arabian
peninsula
new
viru
subsequ
renam
middl
east
respiratori
syndrom
coronaviru
mer
cov
diseas
refer
simpli
mer
genet
sequenc
analysi
human
coronavirus
divid
coronavirus
three
distinct
phylogenet
group
mer
cov
sever
acut
respiratori
syndrom
coronaviru
sar
cov
coronavirus
howev
sar
cov
map
subgroup
wherea
mer
cov
map
subgroup
agnihothram
jid
chan
j
infect
mer
typic
present
upper
respiratori
tract
infect
uncommon
howev
diseas
progress
acut
respiratori
distress
syndrom
ard
multiorgan
failur
arabi
aim
mortal
highest
among
elderli
comorbid
ill
especi
underli
lung
cardiac
diseas
arabi
aim
saad
int
j
infect
di
novemb
laboratoryconfirm
mer
case
mer
relat
death
yield
mortal
rate
approxim
among
confirm
case
high
among
earliest
case
saudi
arabia
recent
survey
bank
sera
saudi
arabian
patient
present
hospit
outpati
care
includ
individu
signific
camel
exposur
reveal
sampl
posit
data
investig
extrapol
mani
individu
countrywid
may
seroposit
muller
lancet
infect
di
suggest
asymptomat
less
sever
ill
may
uncommon
overal
mortal
rate
may
much
lower
report
june
individu
return
south
korea
busi
trip
arabian
peninsula
develop
succumb
progress
respiratori
ill
later
confirm
caus
mer
cov
delay
diagnosi
coupl
seek
care
multipl
health
care
facil
consequ
widespread
transmiss
result
case
death
although
mortal
rate
korean
outbreak
less
transmiss
hospit
famili
contact
rais
alarm
potenti
even
larger
outbreak
transmiss
hospit
set
alreadi
common
among
mer
case
saudi
arabia
europ
arabi
ann
int
med
gueri
lancet
moreov
mer
cov
epidem
result
signific
neg
impact
korean
economi
gdp
slow
growth
compar
year
prior
approv
therapi
vaccin
mer
cov
infect
although
numer
treatment
strategi
investig
vitro
anim
model
none
progress
human
evalu
novemb
vaccin
concept
develop
includ
dna
plasmid
protein
prime
follow
protein
boost
wang
develop
vaccin
candid
mer
cov
inform
experi
sar
cov
howev
two
small
phase
sar
cov
vaccin
trial
complet
two
addit
phase
trial
withdrawn
prior
enrol
martin
et
al
report
studi
dna
vaccin
express
sprotein
sar
cov
particip
vaccin
mgvaccin
dose
seri
martin
vaccin
seriou
advers
event
sae
grade
ae
common
reaction
mild
inject
site
pain
neutral
antibodi
respons
detect
plaqu
assay
although
particip
detect
neutral
titer
lentiviru
pseudotyp
assay
five
individu
reciproc
titer
rang
transient
week
declin
baselin
week
elispot
measur
cell
respons
show
achiev
cell
specif
reaction
threshold
two
achiev
spot
count
versu
manifest
cell
respons
time
point
albeit
spot
second
phase
clinic
trial
conduct
china
list
clinicaltrialsgov
test
inactiv
sar
cov
viru
vaccin
administ
two
dose
without
adjuv
lin
vaccin
sae
report
antibodi
titer
peak
week
follow
second
vaccin
declin
thereaft
seroconvers
document
vaccin
recipi
day
antibodi
titer
persist
threshold
one
recipi
day
two
addit
phase
trial
sar
cov
vaccin
close
prior
enrol
one
test
protein
subunit
vaccin
aluminum
hydroxid
adjuv
second
consist
wholeinactiv
sar
viru
given
without
aluminum
hydroxid
adjuv
thu
two
sar
cov
phase
vaccin
trial
complet
though
neither
yield
safeti
concern
notabl
dna
plasmid
use
current
vaccin
trial
also
target
coronaviru
protein
mediat
viral
entri
target
cell
howev
plasmid
backbon
differ
past
dna
vaccin
sever
import
way
sar
cov
protein
dna
plasmid
vaccin
use
vical
express
vector
modifi
contain
human
cell
leukemia
safeti
also
inform
past
experi
similar
inovio
vaccin
candid
complet
human
clinic
trial
specif
exampl
includ
phase
trial
human
papilloma
viru
hpv
dna
vaccin
incorpor
hpv
protein
hpv
modifi
backbon
administ
without
plasmid
dna
adjuv
bagarazzi
sci
tran
med
trimbl
lancet
current
studi
includ
hepat
c
vaccin
particip
chronic
infect
ebola
viru
vaccin
use
plasmid
backbon
differ
antigen
insert
product
date
well
toler
elicit
sae
emerg
reemerg
infecti
diseas
pose
signific
threat
militari
oper
tend
high
case
fatal
rate
often
unpredict
spread
occur
across
area
servic
member
deploy
diseas
may
aris
within
militari
commun
spillov
surround
civilian
populac
militari
oper
deploy
novel
infecti
agent
pose
challeng
earli
detect
prevent
strategi
particularli
militari
personnel
resid
deploy
endem
area
mer
cov
specif
grow
global
concern
given
airborn
rout
transmiss
high
fatal
rate
therefor
may
impact
militari
oper
readi
central
dna
plasmid
compon
studi
immunogen
mice
camel
rhesu
macaqu
also
part
challeng
model
protect
mer
cov
infect
nonhuman
primat
infect
model
use
rhesu
macaqu
muthumani
sci
transl
med
follow
immun
mice
manifest
high
bind
antibodi
titer
follow
two
immun
endpoint
titer
follow
three
immun
neutral
titer
exceed
follow
three
immun
cell
respons
mice
mer
protein
broad
base
reactiv
cell
span
entir
protein
magnitud
cell
mediat
respons
spot
form
unit
per
pbmc
abil
induc
protect
immun
respons
also
assess
camel
like
intermedi
host
mer
camel
immun
three
inject
mg
per
inject
space
week
apart
found
develop
bind
antibodi
anim
camel
gener
detect
neutral
antibodi
final
nonhuman
primat
immun
either
low
dose
mgvaccin
high
dose
mgvaccin
three
vaccin
space
week
apart
notabl
singl
vaccin
anim
given
low
dose
macaqu
given
high
dose
vaccin
seroconvert
bind
antibodi
titer
two
vaccin
anim
seroconvert
manifest
endpoint
bind
antibodi
titer
neutral
antibodi
titer
three
inject
without
distinct
high
lowdos
vaccin
cytotox
respons
broad
base
across
mer
protein
domin
respons
correspond
receptor
bind
region
magnitud
respons
three
vaccin
approxim
pbmc
importantli
magnitud
cell
respons
signific
breadth
respons
almost
cell
reactiv
immun
gene
express
plasmid
dna
use
effici
mean
express
target
protein
vaccin
relat
immun
respons
replac
augment
natur
occur
protein
enzym
dna
plasmid
part
vaccin
trial
develop
varieti
infecti
diseas
number
test
part
phase
andor
phase
ii
clinic
trial
human
result
first
dna
plasmidbas
vaccin
trial
publish
hiv
macgregor
jid
particip
vaccin
avian
influenza
also
employ
nonintegr
plasmid
base
express
system
insert
compris
portion
viral
dna
repres
consensu
sequenc
found
natur
improv
immun
respons
viral
target
enhanc
breadth
reaction
across
differ
viral
strain
studi
along
addit
studi
sponsor
inovio
pharmaceut
formerli
vgx
pharmaceut
enumer
tabl
case
phase
ii
studi
shown
evid
signific
vaccineassoci
toxic
primari
advers
event
report
transient
inject
site
reaction
electropor
ep
enhanc
gene
express
plasmid
dna
deliv
intramuscular
im
intraderm
id
rout
administr
follow
im
id
deliveri
dna
vaccin
therapeut
product
ep
facilit
entri
dna
target
site
muscl
dermal
cell
follow
cellular
uptak
effici
increas
product
protein
encod
dna
express
system
differ
ep
devic
vari
electr
paramet
protocol
review
prudhomm
curr
gene
ther
ep
extens
use
larg
anim
speci
dog
pig
cattl
nhp
deliv
therapeut
gene
encod
varieti
hormon
cytokin
enzym
antigen
prudhomm
curr
gene
ther
activ
cellular
humor
respons
anim
model
hirao
vaccin
rosati
vaccin
importantli
immun
respons
dna
vaccin
deliv
ep
far
superior
vaccin
without
ep
rosati
vaccin
im
deliveri
dna
ep
well
studi
optimum
condit
plasmid
uptak
express
describ
therapeut
indic
vaccin
tumor
anim
model
system
curcio
cancer
gene
ther
ugen
cancer
gene
ther
inovio
pharmaceut
novel
constant
current
im
ep
devic
prudhomm
curr
gene
ther
refer
cellectra
cellectra
devic
use
clinic
trial
juli
human
subject
undergon
ep
cellectra
devic
differ
studi
dose
dna
administ
signific
find
moder
selfresolv
administr
site
pain
evalu
cpk
muscl
damag
ecg
cardiac
conduct
abnorm
unremark
signific
eprel
safeti
issu
identifi
contain
singl
plasmid
steril
water
inject
wfi
distinguish
name
eukaryot
express
plasmid
contain
dna
encod
fulllength
mer
cov
protein
incorpor
consensu
sequenc
publish
mer
cov
clinic
isol
strain
protein
dna
sequenc
codon
optim
mammalian
express
transcript
unit
control
synthet
cmv
promot
element
requir
replic
select
e
coli
name
puc
origin
replic
pucori
kanamycin
resist
gene
kanr
respect
human
respons
unknown
studi
assess
safeti
toler
immunogen
base
prior
experi
treatment
hiv
infect
dose
mg
correspond
vaccin
dose
approxim
preclin
studi
rhesu
macaqu
assess
high
mgvaccin
low
mgvaccin
dose
robust
tcell
immun
respons
human
elicit
dose
mgvaccin
similar
dna
construct
phase
doserang
studi
treatment
cervic
dysplasia
relat
hpv
cervic
infect
bagarazzi
sci
transl
med
trimbl
lancet
preliminari
analysi
human
respons
treatment
hepat
c
show
minim
immunolog
benefit
sinc
dose
increas
mg
mg
small
increas
immun
respons
notabl
hpv
product
base
express
system
use
construct
assess
antibodi
tcell
respons
follow
vaccin
determin
effect
vaccin
followup
determin
longev
immunogen
accord
intern
confer
harmonis
ich
studi
design
minim
risk
studi
particip
potenti
risk
studi
product
administr
studi
use
similar
plasmid
ident
dna
backbon
list
tabl
sinc
volunt
clinic
trial
healthi
first
man
studi
direct
benefit
expect
potenti
side
effect
treatment
investig
product
may
includ
discomfort
relat
ep
techniqu
local
edema
swell
pain
system
side
effect
vaccin
base
ident
backbon
demonstr
gener
minim
particip
sinc
volunt
clinic
trial
healthi
direct
benefit
expect
potenti
benefit
determin
whether
vaccin
gener
protect
level
neutral
antibodi
cytotox
tcell
prophylact
treatment
risk
mer
cov
infect
princip
risk
studi
personnel
exposur
clinic
set
infecti
pathogen
studi
particip
variou
contact
mechan
eg
needl
stick
exposur
blood
born
pathogen
exposur
respiratori
pathogen
upper
respiratori
tract
infect
adher
good
hygien
practic
standard
oper
procedur
sop
work
infecti
agent
univers
precaut
reduc
risk
exposur
known
risk
environ
associ
gener
geneon
life
scienc
inc
clinic
protocol
wast
attend
vaccin
human
biohazard
wast
dispos
stipul
local
state
feder
regul
accord
studi
site
sop
discomfort
needl
stick
blood
draw
possibl
includ
swell
bruis
small
risk
infect
site
needl
stick
particip
may
feel
lighthead
may
develop
rapid
heartbeat
blood
collect
symptom
stop
particip
lie
andor
stop
procedur
investig
new
drug
ind
product
potenti
risk
seriou
even
lifethreaten
allerg
reaction
vaccin
mitig
risk
potenti
particip
histori
sever
allerg
reaction
kind
signific
allerg
reaction
known
compon
experiment
product
exclud
particip
vaccin
formul
steril
water
allerg
reaction
would
like
due
dna
vaccin
event
sever
allerg
reaction
ctc
staf
train
medic
personnel
stock
appropri
medic
emerg
equip
provid
acut
care
condit
anaphylaxi
requir
formal
emerg
medic
respons
servic
fire
depart
capabl
treat
transfer
lifethreaten
injuri
higher
level
medic
care
avail
close
proxim
trial
site
ep
devic
deliv
three
brief
less
second
electr
impuls
deltoid
quadricep
muscl
electrod
result
brief
intens
muscl
contract
puls
associ
local
paindiscomfort
period
ep
administr
addit
ae
associ
procedur
past
includ
minor
transient
cutan
bleed
site
electrod
inject
needl
penetr
mild
moder
inject
site
sorenessbruis
typic
last
hour
instanc
day
post
administr
one
occas
vaccin
earli
phase
anoth
studi
separ
ep
devic
inject
needl
came
contact
volunt
periosteum
creat
resist
vaccin
attempt
withdraw
devic
never
report
ep
devic
howev
minim
risk
volunt
bodi
mass
index
measur
studi
baselin
less
guard
use
devic
prevent
electrod
insert
full
length
volunt
arm
addit
even
bodi
mass
index
volunt
greater
princip
investig
deleg
may
still
opt
use
guard
vaccin
volunt
feel
enough
muscl
mass
accommod
electrod
pain
associ
ep
intens
transient
experi
particular
devic
almost
individu
report
complet
disappear
pain
minut
post
ep
addit
potenti
deliveri
excess
electr
energi
skin
muscl
tissu
prevent
devic
design
perform
multipl
selfmonitor
geneon
life
scienc
inc
clinic
protocol
identifi
potenti
unsaf
oper
condit
throughout
vaccin
process
detect
abnorm
result
disconnect
prevent
electr
discharg
subject
occurr
excess
energi
deliveri
nonclin
clinic
studi
conduct
cellectra
devic
although
electrocardiogram
safe
procedur
potenti
harm
may
come
discoveri
previous
known
cardiac
condit
inform
howev
kept
confidenti
use
refer
particip
appropri
care
treatment
risk
data
collect
particip
result
hiv
hepat
b
hepat
c
infect
could
becom
public
result
social
harm
mitig
follow
confidenti
procedur
describ
leukapheresi
procedur
perform
studi
center
studi
procedur
wrair
ctc
robert
grant
ave
silver
spring
md
american
red
cross
personnel
respons
perform
procedur
contract
wrair
essenti
plasmapheresi
perform
approxim
plasma
remov
patient
cours
hour
major
fraction
red
blood
cell
return
volunt
fraction
plasma
primari
interest
peripher
blood
mononuclear
cell
procedur
refer
leukapheresi
throughout
protocol
procedur
leukapheresi
offer
week
visit
subset
volunt
chosen
option
procedur
requir
addit
consent
interim
analysi
conduct
subset
volunt
per
dose
group
week
visit
determin
five
highest
immun
respond
measur
neutral
antibodi
titer
five
individu
recruit
leukapheresi
substudi
next
five
highest
respond
recruit
first
five
declin
subset
particip
chosen
procedur
make
effici
use
leukapheresi
focus
provid
highest
yield
potent
neutral
antibodi
addit
leukocyt
collect
later
time
point
antibodi
affin
matur
suffici
risk
leukapheresi
procedur
includ
follow
blood
loss
inabl
return
red
blood
cell
autom
plasmapheresi
may
result
procedur
termin
allerg
reaction
flush
itch
hive
abdomin
cramp
difficulti
breath
may
vari
sever
mild
lifethreaten
vascular
injuri
needl
use
procedur
includ
bruis
hematoma
venipunctur
site
may
present
pain
tingl
paresthesia
presyncopalsyncop
episod
volum
remov
includ
pallor
weak
lightheaded
agit
sweat
nausea
vomit
hypotens
tachycardia
bradycardia
faint
incontin
side
effect
close
monitor
immedi
procedur
normal
salin
reinfus
perform
conjunct
plasmapheresi
reduc
likelihood
reaction
reaction
anticoagul
use
plasmapheresi
includ
follow
tingl
paresthesia
muscl
cramp
tetani
seizur
metal
tast
mouth
geneon
life
scienc
inc
clinic
protocol
recent
analysi
apheresi
procedur
includ
plasmapheresi
us
estim
risk
moder
sever
advers
reaction
risk
mitig
limit
volum
plasma
remov
care
screen
modern
equip
experi
personnel
volunt
monitor
close
train
american
red
cross
medic
personnel
procedur
wait
clinic
minut
procedur
risk
data
collect
particip
could
unintent
releas
anoth
parti
constitut
breach
confidenti
potenti
caus
social
harm
risk
also
compound
militari
personnel
may
inform
leak
chain
command
although
militari
personnel
activ
recruit
studi
risk
mitig
univers
practic
within
research
clinic
complet
mainten
confidenti
among
studi
staff
limit
use
particip
identifi
studi
materi
lock
print
materi
relat
studi
particip
password
protect
electron
document
relat
studi
research
remot
possibl
risk
unknown
foreseen
base
avail
inform
would
includ
late
effect
seen
vaccin
hypothesi
administ
intramuscularli
im
follow
ep
well
toler
immunogen
evalu
safeti
toler
administ
im
inject
follow
ep
healthi
adult
particip
incid
advers
event
classifi
system
organ
class
soc
prefer
term
pt
sever
relationship
studi
treatment
schedul
administr
inject
site
reaction
describ
frequenc
sever
grade
administr
site
pain
chang
safeti
laboratori
paramet
describ
frequenc
sever
grade
eg
liver
panel
test
vital
sign
evalu
cellular
humor
respons
deliv
im
follow
ep
evalu
dose
respons
cellular
humor
reactiv
deliv
im
follow
ep
quantit
bind
antibodi
titer
full
length
mer
cov
spike
glycoprotein
qualit
quantit
level
neutral
antibodi
mer
cov
antigen
specif
cellular
immun
respons
mer
cov
determin
interferongamma
elispot
intracellular
cytokin
stain
ic
cytotox
lymphocyt
phenotyp
lytic
granul
load
granzym
b
kill
target
cell
explor
whether
end
point
antibodi
titer
mer
cov
protein
dose
relat
explor
time
onset
antibodi
product
longev
serolog
respons
explor
increas
dose
level
rapidli
induc
cellular
immun
explor
time
onset
cell
respons
longev
cell
mediat
immun
evalu
kinet
antigen
express
peripher
blood
compart
evalu
host
genet
potenti
predictor
vaccin
immun
respons
host
immunegenotyp
resourc
avail
epitop
map
lymphocyt
respons
immunophenotyp
function
character
cellular
subset
interest
includ
natur
killer
nk
cell
isol
express
character
monoclon
antibodi
mer
cov
protein
assess
neutral
nonneutr
function
activ
molecular
character
studi
vaccineelicit
antibodi
may
includ
limit
structur
biolog
analysi
fc
analysi
isotyp
analysi
epitop
map
correl
endpoint
antibodi
bind
titer
across
two
differ
elisa
platform
phase
openlabel
trial
assess
safeti
toler
immunogen
encod
protein
mer
cov
elig
particip
consent
particip
administ
via
im
inject
follow
immedi
ep
use
cellectra
adapt
constant
current
electropor
devic
prospect
particip
read
sign
inform
consent
form
icf
screen
elig
day
prior
first
dose
screen
evalu
consist
medic
histori
ecg
laboratori
evalu
particip
without
histori
exclusionari
condit
clinic
signific
normal
ecg
grade
laboratori
valu
per
toxic
grade
scale
healthi
adult
appendix
b
cbc
serum
chemistri
cpk
elig
particip
trial
total
particip
divid
group
enrol
studi
estim
approxim
particip
need
screen
fill
desir
enrol
particip
group
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
group
ii
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
group
iii
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
particip
enrol
lowest
dose
group
continu
enrol
week
enrol
start
week
clinic
laboratori
data
first
five
particip
group
review
part
safeti
review
safeti
lab
review
clear
first
five
particip
group
second
dose
level
open
next
five
particip
met
elig
criteria
enrol
group
ii
enrol
group
complet
group
complet
enrol
particip
group
popul
sequenti
first
five
particip
group
reach
one
week
post
vaccin
safeti
lab
review
safeti
assess
clear
group
iii
open
enrol
next
five
particip
enrol
complet
group
tabl
summari
studi
treatment
schedul
dose
safeti
assess
particip
monitor
local
system
advers
event
ae
studi
visit
laboratori
relat
ae
follow
first
second
third
vaccin
immunogen
assess
studi
explor
humor
cell
mediat
immun
respons
blood
sampl
collect
follow
time
studi
util
treatment
progress
scheme
assess
ensur
safeti
dose
level
vaccin
follow
particip
contact
telephon
assess
reaction
day
follow
st
vaccin
assess
whether
report
ae
reaction
doselimit
ae
report
first
particip
enrol
enrol
proceed
remaind
particip
dose
level
safeti
laboratori
assess
perform
week
st
dose
vaccin
week
nd
rd
dose
studi
particip
grade
grade
ae
seriou
advers
event
sae
note
either
clinic
assess
safeti
laboratori
assess
first
particip
enrol
dose
level
enrol
next
higher
dose
level
open
lab
forward
review
monthli
basi
thereaft
particip
complet
safeti
lab
draw
safeti
monitor
committe
safeti
monitor
conduct
throughout
studi
therefor
safeti
concern
identifi
continu
review
data
pi
clinic
staff
clinic
monitor
dod
research
monitor
studi
repres
first
time
administ
human
investig
team
also
establish
safeti
monitor
committe
smc
review
safeti
lab
provid
oversight
safe
conduct
studi
addit
measur
address
mitig
risk
smc
consist
studi
pi
medic
monitor
dod
research
monitor
safeti
review
conduct
weekli
basi
either
teleconfer
electron
urgent
issu
need
address
smc
conven
ad
hoc
address
issu
enrol
one
dose
level
next
requir
approv
review
member
safeti
geneon
life
scienc
inc
clinic
protocol
summar
safeti
data
smc
protocol
consider
sentinel
group
five
volunt
doselevel
safeti
report
includ
laboratori
monitor
data
timefram
cover
assess
move
forward
provid
vice
chair
review
option
refer
conven
irb
smc
review
unanticip
problem
involv
risk
subject
other
sae
subject
death
associ
protocol
provid
unbias
written
report
event
smc
also
review
withdraw
discontinu
studi
particip
volunt
determin
product
relat
smc
also
paus
studi
paus
rule
met
outlin
section
notifi
irb
immedi
paus
report
event
determin
either
investig
entir
smc
relat
unrel
particip
report
event
result
death
promptli
forward
irb
research
monitor
function
independ
safeti
advoc
subject
per
ar
dod
instruct
independ
research
monitor
requir
review
unanticip
problem
involv
risk
subject
other
sae
subject
death
associ
protocol
provid
unbias
written
report
event
minimum
research
monitor
comment
outcom
event
problem
case
sae
death
comment
relationship
particip
studi
research
monitor
also
indic
whether
hesh
concur
detail
report
provid
studi
investig
report
event
determin
either
investig
research
monitor
possibl
definit
relat
particip
report
event
result
death
forward
wrair
irb
orp
hrpo
usamrmc
cssd
pssb
sponsor
safeti
offic
within
hour
follow
written
report
within
work
day
per
wrair
sop
safeti
report
clinic
trial
duti
research
monitor
shall
determin
basi
specif
risk
concern
research
research
monitor
may
perform
oversight
function
need
eg
observ
recruit
enrol
procedur
consent
process
individu
group
unit
overse
studi
intervent
interact
review
monitor
plan
upirtso
report
overse
data
match
data
collect
analysi
report
observ
find
irb
design
offici
research
monitor
may
discuss
research
protocol
investig
interview
human
subject
consult
other
outsid
studi
research
research
monitor
shall
author
stop
research
protocol
progress
remov
individu
human
subject
research
protocol
take
whatev
step
necessari
protect
safeti
wellb
human
subject
irb
assess
monitor
report
research
monitor
shall
respons
promptli
report
observ
find
irb
design
offici
weekli
report
gener
contract
statist
support
group
report
compris
frequenc
sae
aesi
well
enrol
statu
number
volunt
screen
number
volunt
screen
failur
basic
laboratori
ecg
demograph
data
dose
group
prior
week
compar
entir
studi
period
date
smc
review
summar
safeti
data
data
appropri
weekli
meet
geneon
life
scienc
inc
clinic
protocol
decis
describ
section
smc
prepar
review
individu
event
thought
major
signific
alert
sponsor
irb
fda
safeti
concern
regard
continu
studi
statist
support
data
monitor
effort
includ
gener
data
safeti
report
mainten
archiv
electron
copi
dataset
statist
program
use
gener
report
gener
updat
carri
statist
analysi
plan
healthi
adult
volunt
male
femal
militari
civilian
recruit
noncoerc
mean
wrair
ctc
accord
applic
us
armi
regul
recruit
advertis
multipl
media
format
email
websit
social
media
newspap
radio
televis
well
word
mouth
recruit
may
also
includ
oral
present
andor
distribut
approv
recruit
materi
event
meet
brief
wherein
desir
recruit
popul
might
reason
expect
attend
recruit
may
includ
referr
potenti
particip
individu
alreadi
screen
studi
particip
ask
direct
interest
person
contact
ctc
particip
receiv
refer
person
attend
screen
session
meet
inclus
none
exclus
criteria
compens
independ
refer
person
decis
enrol
final
author
dispens
referr
compens
lie
ctc
director
advertis
gener
specif
studi
review
approv
wrair
irb
prior
use
recruit
method
direct
volunt
contact
ctc
via
email
phone
ctc
web
site
contact
inform
given
upon
call
recruit
phone
number
irb
approv
recruit
script
use
studi
personnel
inform
potenti
particip
detail
studi
potenti
particip
desir
basic
contact
inform
obtain
appoint
formal
brief
screen
made
time
upon
contact
ctc
via
email
potenti
particip
provid
electron
version
recruit
script
inform
detail
studi
potenti
particip
desir
basic
contact
inform
obtain
appoint
formal
brief
screen
made
via
email
phone
convers
volunt
also
recruit
via
wrair
gener
screen
protocol
manag
wrair
ctc
screen
protocol
volunt
undergo
gener
screen
visit
medic
histori
exam
vital
lab
test
along
potenti
screen
test
volunt
interest
learn
clinic
trial
need
attend
wrair
studi
specif
brief
screen
appoint
particip
remain
interest
need
sign
studi
inform
consent
form
volunt
consent
screen
document
wrair
share
studi
fulfil
screen
requir
copi
said
document
ad
volunt
studi
file
clinic
trial
militari
particip
recruit
format
research
monitor
act
ombudsman
studi
present
independ
parti
ombudsman
avail
help
answer
question
imparti
standpoint
addit
senior
nco
offic
present
recruit
brief
ensur
undu
pressur
influenc
soldier
immedi
chain
command
age
year
militari
civilian
male
femal
b
abl
provid
consent
particip
sign
inform
consent
form
c
abl
will
compli
studi
procedur
women
childbear
potenti
agre
remain
sexual
abstin
use
medic
effect
contracept
oral
contracept
barrier
method
spermicid
etc
partner
steril
enrol
month
follow
last
inject
partner
unabl
induc
pregnanc
e
sexual
activ
men
consid
sexual
fertil
must
agre
use
either
barrier
method
contracept
studi
agre
continu
use
least
month
follow
last
inject
partner
perman
steril
unabl
becom
pregnant
f
normal
screen
ecg
screen
ecg
clinic
signific
find
f
administr
monoclon
polyclon
antibodi
product
within
week
first
dose
g
administr
blood
product
within
month
first
dose
h
pregnanc
breast
feed
plan
becom
pregnant
cours
studi
histori
posit
serolog
test
hiv
hepat
b
surfac
antigen
hbsag
potenti
communic
infecti
diseas
determin
princip
investig
medic
monitor
j
posit
serolog
test
hepat
c
except
success
treatment
confirm
sustain
virolog
respons
k
baselin
evid
kidney
diseas
measur
creatinin
greater
ckd
stage
ii
greater
geneon
life
scienc
inc
clinic
protocol
baselin
screen
lab
grade
higher
abnorm
chronic
liver
diseas
cirrhosi
n
immunosuppress
ill
includ
hematolog
malign
histori
solid
organ
bone
marrow
transplant
current
anticip
concomit
immunosuppress
therapi
exclud
inhal
topic
skin
andor
eye
dropcontain
corticosteroid
lowdos
methotrex
corticosteroid
dose
less
mgday
p
current
anticip
treatment
inhibitor
infliximab
adalimumab
etanercept
q
prior
major
surgeri
radiat
therapi
within
week
group
assign
r
preexcit
syndrom
eg
wolffparkinsonwhit
syndrom
presenc
cardiac
pacemak
automat
implant
cardiovert
defibril
aicd
metal
implant
within
cm
plan
site
inject
u
presenc
keloid
scar
format
hypertroph
scar
clinic
signific
medic
condit
plan
site
inject
v
prison
particip
compulsorili
detain
involuntari
incarcer
treatment
either
physic
psychiatr
ill
w
activ
drug
alcohol
use
depend
opinion
investig
would
interfer
adher
studi
requir
assess
immunolog
endpoint
x
tattoo
cover
inject
site
area
h
ill
condit
opinion
investig
may
affect
safeti
particip
evalu
studi
endpoint
particip
consid
complet
studi
hesh
complet
schedul
studi
treatment
followup
visit
particip
discontinu
studi
time
dose
investig
make
everi
effort
particip
complet
assess
indic
section
safeti
paramet
investig
make
everi
effort
schedul
immun
assess
blood
sampl
collect
indic
schedul
event
tabl
unless
particip
refus
continu
particip
followup
visit
procedur
complet
indic
schedul
event
tabl
follow
last
dose
whether
particip
complet
dose
data
collect
time
withdraw
includ
final
evalu
lab
result
may
pend
time
withdraw
report
likewis
specimen
collect
time
withdraw
includ
blood
collect
storag
use
futur
research
kept
util
outlin
protocol
consent
form
studi
termin
ecrf
complet
reason
withdraw
specifi
reason
discontinu
investig
product
discuss
sponsor
medic
monitor
indic
studi
form
primari
reason
particip
discontinu
dose
withdraw
studi
select
follow
standard
categori
advers
event
advers
reaction
clinic
laboratori
event
occur
medic
judgment
investig
ground
discontinu
best
interest
withdraw
consent
particip
desir
withdraw
particip
studi
absenc
investigatordetermin
medic
need
withdraw
particip
gave
reason
withdraw
must
record
crf
reason
allow
data
collect
later
studi
relat
procedur
protocol
violat
particip
fail
meet
protocol
entri
criteria
fail
adher
protocol
requir
eg
treatment
noncompli
failur
return
defin
number
visit
violat
discuss
sponsor
medic
monitor
prior
discontinu
either
studi
treatment
studi
withdraw
lost
followup
particip
fail
attend
studi
visit
studi
personnel
unabl
contact
particip
repeat
attempt
includ
letter
sent
certifi
mail
equival
physician
decis
particip
termin
reason
list
physician
care
particip
incarcer
particip
prison
plan
volunt
suspend
studi
visit
incarcer
irb
notifi
period
incarcer
possibl
site
team
coordin
correct
author
ensur
relev
medic
inform
safeti
care
patient
commun
promptli
particip
termin
reason
list
termin
studi
sponsor
investig
product
investig
product
use
studi
contain
dna
plasmid
encod
protein
mer
cov
product
provid
concentr
approxim
mgml
dilut
mix
site
need
dose
standard
ml
volum
administ
studi
particip
concentr
final
plasmid
vari
base
dosag
administ
solut
steril
water
inject
swfi
therefor
swfi
use
dilut
biolog
product
clinic
site
formul
vaccin
product
ship
manufactur
vgxi
houston
texa
dri
ice
lot
number
vaccin
use
ip
studi
complet
fda
review
novemb
notif
protocol
clinic
hold
receiv
clinic
trial
could
proceed
prior
fda
submiss
either
alon
combin
product
studi
product
suppli
nonblind
fashion
indic
particular
compon
studi
product
ship
directli
manufactur
designe
studi
site
vial
label
singl
panel
label
vial
label
text
may
includ
follow
minim
recover
volum
indic
studi
product
account
perform
continu
studi
detail
studi
product
volum
administr
account
document
crf
respect
pharmaci
form
completiontermin
studi
unus
partial
use
suppli
must
return
geneon
life
scienc
inc
investig
pharmacistdrug
administr
medic
monitor
must
verifi
drug
suppli
remain
site
time
studi
closeout
appropri
record
maintain
investig
site
file
geneon
life
scienc
inc
respons
assur
qualiti
investig
product
adequ
durat
trial
ship
dri
ice
dri
ice
remain
frozen
shipment
contain
shipment
receiv
sponsor
must
contact
immedi
investig
product
must
store
secur
area
accord
local
regul
studi
product
must
transfer
ship
contain
appropri
storag
condit
upon
arriv
must
store
frozen
freezer
frostfre
although
long
term
storag
approxim
month
must
store
refrigeratorfreez
temperatur
log
must
maintain
clinic
site
temperatur
must
record
monitor
regularli
respons
investig
ensur
dispens
studi
particip
author
personnel
offici
studi
site
must
one
dispens
product
accord
local
regul
dose
syring
must
label
fourhour
expir
date
time
vial
remov
storag
label
also
contain
word
administ
soon
possibl
detail
instruct
handl
dispens
investig
product
provid
dose
studi
product
known
suspect
taken
accident
intent
excess
dose
mandat
protocol
misus
abus
studi
product
product
taken
concomit
medic
whether
associ
advers
experi
must
report
geneon
life
scienc
within
hour
clinic
sequela
geneon
life
scienc
inc
clinic
protocol
overdos
report
ae
sae
detail
sign
symptom
clinic
manag
outcom
report
avail
suppli
singl
dose
ml
vial
concentr
mgml
volum
ml
minimum
recover
volum
combin
swfi
requir
volum
concentr
experienc
site
personnel
im
administr
detail
instruct
investig
product
prepar
provid
pharmaci
manual
respons
investig
ensur
current
record
investig
product
disposit
maintain
studi
site
investig
product
inventori
dispos
record
log
must
compli
applic
regul
guidelin
includ
amount
receiv
place
storag
area
amount
current
storag
area
label
id
number
batch
number
use
date
expiri
date
date
initi
person
respons
investig
product
inventori
entrymov
amount
dispens
particip
includ
uniqu
particip
identifi
amount
transfer
anoth
areasit
dispens
storag
amount
return
sponsor
amount
destroy
studi
site
applic
upon
complet
termin
studi
unus
andor
partial
use
investig
product
must
return
geneon
life
scienc
inc
designe
author
geneon
life
scienc
inc
destroy
site
investig
product
return
geneon
life
scienc
inc
designe
must
accompani
appropri
document
return
suppli
origin
contain
empti
contain
return
geneon
life
scienc
inc
investig
respons
arrang
dispos
empti
contain
provid
procedur
proper
dispos
establish
accord
applic
feder
state
local
institut
guidelin
procedur
provid
appropri
record
dispos
kept
return
unus
investig
product
arrang
respons
studi
monitor
investig
product
destroy
site
investig
respons
ensur
arrang
made
dispos
written
author
grant
geneon
life
scienc
inc
designe
procedur
proper
dispos
establish
accord
applic
regul
guidelin
institut
procedur
appropri
record
dispos
document
unus
investig
product
destroy
inspect
reconcil
respons
geneon
life
scienc
inc
design
studi
monitor
instruct
use
cellectra
devic
locat
oper
manual
clinic
site
receiv
train
use
cellectra
devic
follow
specif
use
studi
number
puls
per
treatment
maximum
current
strength
amper
voltag
strength
volt
electropor
puls
durat
millisecondspuls
interv
separ
puls
second
ep
needl
array
length
inject
depth
mm
array
guid
place
mm
without
array
guid
vaccinationelectropor
procedur
perform
qualifi
personnel
licens
healthcar
provid
design
perform
procedur
must
appropri
licens
administ
vaccin
parenter
drug
particip
eg
md
rn
lpn
addit
administ
vaccin
train
manufactur
correct
use
cellectra
electropor
devic
individu
design
perform
ep
procedur
must
satisfactorili
complet
devic
train
sponsor
designe
regardless
qualif
deviat
procedur
must
approv
sponsor
designe
clinic
site
respons
maintain
investig
devic
account
includ
record
cellectra
serial
number
applic
serial
number
array
lot
number
use
treatment
ep
particip
see
tabl
clinic
protocol
synopsi
schedul
event
show
studi
procedur
time
carri
assess
screen
phase
determin
particip
elig
studi
also
abil
compli
protocol
requir
complet
screen
assess
follow
addit
screen
evalu
perform
within
day
prior
dose
day
screen
assess
valu
must
review
prior
studi
treatment
sign
inform
consent
may
includ
consent
photographi
consent
inject
site
may
photograph
event
unusu
highgrad
inject
site
reaction
investig
discret
section
review
confirm
inclusionexclus
criteria
section
collect
demograph
includ
gender
ethnic
origin
obtain
complet
medic
histori
includ
procedur
histori
present
condit
concomit
ill
section
record
concomit
medicationstreat
present
past
week
geneon
life
scienc
inc
clinic
protocol
record
vital
sign
includ
bodi
weight
height
heart
rate
hr
blood
pressur
bp
respir
rate
oral
temperatur
section
collect
blood
cbc
differenti
blood
chemistri
sodium
na
potassium
k
chlorid
cl
bicarbon
glucos
bun
creatinin
ast
alt
cpk
section
collect
blood
serolog
assess
hiv
hepat
b
surfac
antigen
hbsag
hepat
c
antibodi
hcv
serum
pregnanc
test
section
lead
ecg
section
physic
exam
section
determin
propos
site
inject
potenti
particip
notifi
elig
soon
lab
result
avail
assess
made
investig
determin
elig
particip
schedul
initi
vaccin
day
visit
regardless
elig
enrol
individu
inform
screen
follow
visit
significantli
abnorm
test
result
expediti
manner
via
telephon
person
written
commun
appropri
counsel
given
regard
necessari
medic
followup
inform
individu
evid
report
infecti
diseas
eg
hiv
hepat
transmit
requir
militari
andor
civilian
public
health
author
applic
potenti
particip
notifi
possibl
inform
consent
process
follow
procedur
perform
vaccin
visit
follow
studi
evalu
perform
prior
dose
review
medic
histori
screen
concomit
medicationstreat
vital
sign
urin
pregnanc
test
applic
collect
whole
blood
week
occur
final
particip
assign
dose
group
ie
mgdose
mgdose
mgdose
serum
particip
visit
regardless
dose
group
immun
assess
pbmc
ship
sponsor
process
collect
plan
monday
thru
friday
blood
must
receiv
pbmc
process
lab
within
hour
collect
shipment
sampl
sponsor
friday
requir
prior
approv
sponsor
pbmc
process
lab
administ
studi
treatment
follow
ep
follow
studi
evalu
perform
post
dose
pain
assess
minimum
minut
ep
inject
site
reaction
assess
minimum
minut
vaccin
target
physic
assess
includ
vital
sign
minimum
minut
vaccin
advers
seriou
advers
event
assess
distribut
particip
remind
diari
download
ep
data
devic
within
hour
follow
treatment
onto
usb
storag
devic
forward
geneon
life
scienc
designe
geneon
life
scienc
inc
clinic
protocol
follow
procedur
perform
day
follow
st
vaccin
contact
studi
particip
phone
local
system
inject
site
review
advers
seriou
advers
event
assess
visit
week
follow
procedur
perform
safeti
visit
week
st
inject
concomit
medicationstreat
vital
sign
target
physic
assess
local
system
inject
site
review
advers
seriou
advers
event
assess
collect
blood
safeti
laboratori
assess
cbc
serum
chemistri
cpk
collect
whole
blood
first
particip
assign
dose
group
serum
studi
particip
immun
assess
indic
review
particip
remind
diari
follow
procedur
perform
interv
assess
visit
week
week
follow
st
vaccin
particip
even
pid
assess
week
post
st
dose
particip
odd
pid
assess
week
post
st
dose
vital
sign
target
physic
assess
concomit
medicationstreat
local
system
inject
site
review
advers
seriou
advers
event
assess
collect
whole
blood
th
th
particip
dose
group
serum
studi
particip
immun
assess
indic
base
whether
particip
assign
even
odd
pid
indic
first
two
bullet
point
section
follow
procedur
perform
interv
assess
visit
week
inject
week
month
final
vaccin
week
concomit
medicationstreat
vital
sign
target
physic
assess
local
system
inject
site
review
week
advers
seriou
advers
event
assess
collect
blood
safeti
laboratori
assess
cbc
serum
chemistri
cpk
week
collect
whole
blood
serum
immun
assess
indic
week
follow
procedur
perform
day
follow
st
vaccin
contact
studi
particip
either
phone
person
local
system
inject
site
review
advers
seriou
advers
event
assess
follow
procedur
perform
month
end
treatment
week
visit
concomit
medicationstreat
vital
sign
target
physic
exam
urin
pregnanc
test
applic
advers
event
assess
collect
whole
blood
serum
immun
assess
particip
may
refus
vaccin
andor
termin
particip
studi
time
event
particip
decid
termin
particip
prematur
effort
made
perform
studi
assess
particip
may
also
discontinu
particip
studi
particip
discontinu
princip
investig
safeti
andor
toler
issu
consid
intoler
andor
manag
symptomat
treatment
minimum
assess
week
visit
perform
prior
withdraw
alreadi
complet
case
fatal
outcom
relev
inform
includ
caus
death
concomit
medic
relationship
studi
treatment
underli
diseas
collect
particip
withdraw
consent
data
collect
consent
withdrawn
howev
data
sampl
collect
prior
particip
withdraw
consent
includ
data
analysi
unless
otherwis
specifi
particip
potenti
particip
given
formal
brief
wrair
ctc
investig
brief
gener
last
hour
describ
rational
key
featur
studi
natur
extent
particip
particip
inclusionexclus
criteria
potenti
risk
andor
benefit
particip
allow
opportun
potenti
particip
ask
address
question
concern
might
regard
studi
brief
involv
combin
standard
present
materi
eg
brief
slide
spontan
interact
investig
potenti
particip
standard
materi
approv
wrair
irb
prior
use
follow
formal
brief
prior
undertak
studi
procedur
sign
inform
consent
studi
particip
use
collect
blood
futur
research
obtain
potenti
particip
accord
applic
us
armi
feder
regul
util
irbapprov
materi
specif
state
maryland
consent
hiv
test
consent
photograph
obtain
time
particip
also
requir
sign
copi
inform
sheet
regard
compens
feder
personnel
particip
geneon
life
scienc
inc
clinic
protocol
research
human
subject
attest
understand
compens
polici
feder
employe
research
particip
potenti
particip
opportun
ask
answer
question
might
studi
prior
give
consent
origin
sign
inform
consent
form
particip
kept
file
secur
locat
investig
potenti
particip
receiv
copi
sign
date
written
inform
consent
document
written
inform
provid
particip
complet
inform
consent
particip
provid
medic
histori
undergo
physic
examin
includ
ecg
routin
standard
laboratori
screen
test
includ
complet
blood
count
cbc
serum
basic
metabol
panel
glucos
electrolyt
blood
urea
nitrogen
bun
creatinin
cr
alanin
aminotransferas
alt
aspart
aminotransferas
ast
serum
pregnanc
screen
betahuman
chorion
gonadotropin
femal
viral
serolog
hepat
b
c
hiv
well
virus
studi
screen
histori
physic
examin
laboratori
find
particip
record
appropri
sourc
document
particip
found
seroposit
hepat
b
c
counsel
refer
regular
health
care
provid
public
health
clinic
evalu
deem
appropri
investig
screen
laboratori
may
repeat
necessari
allow
accur
determin
potenti
particip
elig
investig
feel
may
reason
screen
laboratori
abnorm
due
lab
error
normal
physiolog
varianc
individu
minor
laboratori
abnorm
consid
grade
abnorm
use
fda
toxic
scale
deem
clinic
insignific
physician
investig
meet
exclus
criteria
otherwis
defin
may
enrol
studi
particip
exclud
particip
fail
meet
inclus
exclus
criteria
find
opinion
investig
would
increas
risk
advers
outcom
trial
militari
particip
also
need
submit
sign
statement
supervisor
approv
particip
enrol
trial
receiv
emerg
contact
id
card
use
contact
pi
ai
event
emerg
contact
studi
staff
need
particip
must
meet
inclus
exclus
criteria
pi
designe
make
final
decis
elig
elig
particip
given
investig
product
particip
inform
descript
clinic
trial
avail
http
www
gov
requir
us
law
particip
illiter
administr
consent
read
irbapprov
inform
consent
subject
english
particip
either
provid
signatur
person
mark
thumb
print
administr
consent
sign
date
form
copi
consent
form
file
particip
chart
sign
copi
provid
particip
part
icf
particip
ask
consent
contact
later
date
separ
enrol
possibl
followon
trial
determin
whether
addit
dose
vaccin
boost
immun
reactiv
year
post
complet
initi
vaccin
seri
particip
consent
contact
later
trial
affect
particip
primari
protocol
geneon
life
scienc
inc
clinic
protocol
constitut
consent
particip
potenti
subsequ
trial
separ
consent
must
obtain
consent
followon
trial
particip
contact
use
contact
inform
provid
studi
enrol
contact
inform
use
contact
particip
phone
call
visit
particip
also
ask
make
everi
effort
updat
contact
inform
chang
particip
recruit
sequenti
assign
three
treatment
group
base
screen
recruit
begin
lowest
dose
group
first
proceed
higher
dose
group
group
fill
particip
enrol
sequenti
lowest
dose
group
continu
enrol
first
week
start
second
week
safeti
lab
review
first
five
particip
group
safeti
lab
clear
second
dose
level
open
next
five
particip
meet
elig
criteria
consent
studi
enrol
group
addit
group
enrol
complet
total
particip
first
five
particip
group
reach
one
week
safeti
lab
review
safeti
assess
clear
group
open
next
five
particip
meet
elig
criteria
enrol
group
group
enrol
complet
follow
group
particip
consent
assign
uniqu
particip
identif
design
number
pid
identifi
particip
studyrel
procedur
screen
number
combin
protocol
design
plu
subject
number
start
assign
pid
number
reus
reason
copi
sign
date
consent
form
given
particip
inform
regard
particip
pid
screen
date
document
screen
log
particip
deem
elig
criteria
list
protocol
section
select
enrol
particip
clinic
site
contact
sponsor
regist
particip
provid
requir
elig
inform
investig
document
signific
ill
particip
experienc
medic
histori
ill
first
occur
detect
studi
andor
worsen
exist
ill
occur
first
vaccin
document
ae
crf
prior
treatment
defin
administ
week
prior
time
inform
consent
record
crf
prior
medic
concomit
treatment
defin
continu
new
treatment
taken
sign
inform
consent
record
crf
concomit
medic
follow
particip
evalu
safeti
perform
particip
record
post
treatment
reaction
local
system
enter
inform
postvaccin
memori
aid
shown
appendix
even
dose
day
post
dose
local
administr
site
reaction
record
use
suppli
ruler
appendix
b
studi
staff
review
memori
aid
report
event
assess
clinic
signific
record
crf
appropri
although
memori
aid
may
geneon
life
scienc
inc
clinic
protocol
particip
conclus
studi
visit
necessarili
collect
diari
use
sourc
document
studi
staff
evalu
uniqu
memori
aid
entri
accord
toxic
grade
scale
healthi
adult
adolesc
volunt
enrol
prevent
vaccin
clinic
trial
issu
septemb
appendix
b
remind
diari
entri
determin
meet
criteria
grade
higher
advers
event
must
document
advers
event
remind
diari
entri
meet
criteria
grade
higher
ae
per
toxic
grade
scale
clinic
judgment
use
determin
whether
entri
record
ae
case
remind
diari
entri
final
ae
report
ie
grade
agre
reason
must
record
sourc
document
full
physic
examin
conduct
screen
target
physic
assess
perform
visit
determin
investig
direct
per
particip
complaint
inject
site
assess
studi
personnel
minimum
minut
ep
well
follow
visit
vital
sign
includ
oral
temperatur
respir
rate
blood
pressur
heart
rate
measur
specifi
visit
weight
lb
height
collect
specifi
visit
ecg
perform
screen
particip
determin
elig
ecg
includ
measur
ventricular
rate
pr
qr
qt
qtc
assess
whether
ecg
normal
abnorm
abnorm
ecg
interpret
clinic
signific
clinic
signific
dose
delay
event
clinic
signific
abnorm
predos
ecg
review
pi
qualifi
pi
designe
medic
monitor
sponsor
consult
cardiologist
deem
safe
proceed
screen
week
week
week
blood
sampl
taken
test
serum
chemistri
hematolog
approxim
ml
blood
drawn
particip
entir
durat
studi
femal
particip
reproduct
potenti
serum
pregnanc
test
obtain
screen
neg
result
urin
test
must
sensit
least
miuml
must
avail
prior
administr
vaccin
test
posit
indic
particip
pregnant
prior
complet
prescrib
regimen
addit
dose
vaccin
must
given
everi
attempt
made
follow
pregnant
particip
remaind
studi
determin
outcom
pregnanc
particip
ask
particip
substudi
leukapheresi
may
perform
select
time
point
lieu
collect
blood
immun
analysi
particip
ask
provid
consent
trial
particip
consent
affect
particip
main
studi
particip
may
select
particip
leukapheresi
perform
per
wrair
protocol
lieu
collect
blood
immun
assess
week
procedur
take
approxim
hour
particip
particip
ask
particip
substudi
base
interim
analysi
conduct
subset
volunt
per
dose
group
week
visit
determin
five
highest
immun
respond
measur
neutral
antibodi
titer
five
individu
recruit
leukapheresi
substudi
next
five
highest
respond
recruit
first
five
declin
total
cohort
particip
receiv
seri
group
receiv
given
im
inject
follow
ep
cellectra
group
receiv
given
im
inject
follow
ep
cellectra
group
receiv
mg
given
im
inject
follow
ep
cellectra
vaccin
deliv
im
deltoid
follow
immedi
ep
deltoid
suitabl
locat
im
inject
later
quadricep
follow
immedi
ep
see
section
use
cellectra
electropor
devic
vaccin
must
given
within
cm
tattoo
scar
activ
lesionrash
time
initi
dose
design
day
subsequ
dose
schedul
administr
per
schedul
event
tabl
within
hour
follow
studi
treatment
data
download
ep
devic
data
file
creat
sent
sponsor
geneon
life
scienc
inc
designe
email
manag
anxieti
pain
due
ep
procedur
particip
offer
analges
eg
ibuprofen
acetaminophen
emla
cream
andor
injectionep
particip
allerg
contraind
ibuprofen
acetaminophen
may
offer
suitabl
altern
blood
drawn
serum
chemistri
hematolog
assess
visit
list
schedul
event
tabl
list
section
laboratori
ae
assess
grade
see
section
detail
inject
site
assess
studi
personnel
prior
within
minimum
minut
injectionep
particip
given
oral
thermomet
instruct
take
record
oral
temperatur
daili
time
day
also
advis
record
local
system
event
day
vaccin
post
vaccin
diari
appendix
particip
also
queri
regard
occurr
advers
event
concomit
medic
new
onset
chronic
diseas
clinic
visit
particip
remind
contact
studi
personnel
immedi
report
event
may
happen
durat
studi
includ
final
studi
visit
event
record
particip
crf
studi
treatment
procedur
consist
insert
cellectra
electropor
array
needl
electrod
skin
underli
muscl
intramuscular
studi
drug
follow
deliveri
electropor
puls
procedur
broadli
describ
administr
involv
inject
drug
attribut
reaction
eg
pain
erythema
swell
observ
near
site
studi
treatment
procedur
inject
studi
drug
versu
administr
electropor
puls
difficult
necessari
consequ
reaction
aris
studi
treatment
procedur
may
report
administr
site
inject
site
reaction
evalu
administr
inject
site
reaction
throughout
studi
import
specif
possibl
select
appropri
term
see
compon
use
grade
scale
outlin
appendix
b
follow
observ
includ
grade
sever
record
crf
time
occurr
rel
dose
eg
immedi
day
dose
etc
resolut
date
current
correl
immun
mer
cov
entir
defin
clear
neutral
antibodi
direct
surfac
spike
glycoprotein
particular
immunolog
focu
receptorbind
domain
subunit
howev
addit
target
humor
cellular
immun
still
defin
thu
immunogen
assess
measur
known
correl
neutral
antibodi
evalu
potenti
mechan
immun
respons
well
blood
specimen
collect
wrair
ctc
process
us
militari
hiv
research
program
mhrp
laboratori
dr
mark
manak
dr
sheila
peel
specimen
analysi
primari
secondari
immunolog
endpoint
ship
specimen
repositori
actg
laboratori
univers
pennsylvania
addit
specimen
exploratori
endpoint
retain
mhrp
specimen
univers
pennsylvania
geneon
life
scienc
inc
clinic
protocol
sent
batch
shipment
laboratori
dr
gari
kobing
quebec
canada
undergo
analysi
primari
secondari
endpoint
divis
labor
laboratori
assay
provid
tabl
specimen
primari
secondari
analysi
destroy
analys
complet
specimen
exploratori
endpoint
analysi
retain
mhrp
indefinit
dr
gordon
joyc
dr
shelli
krebsand
laboratori
isol
character
monoclon
antibodi
vaccine
high
viru
neutral
antigen
bind
antibodi
respons
also
screen
serum
vaccine
competit
bind
studi
better
character
epitop
vaccineelicit
antibodi
direct
dr
joyc
dr
kreb
laboratorieswil
carri
structur
studi
isol
antibodi
resolv
atom
scale
antigenantibodi
complex
structur
relationship
correl
function
respons
sampl
score
posit
averag
od
greater
absorb
unit
greater
averag
od
immun
plu
time
standard
deviat
sd
od
immun
dilut
result
present
endpoint
titer
ie
last
dilut
od
valu
sampl
meet
criteria
second
elisa
platform
use
compar
volunt
serum
perform
laboratori
david
weiner
wistar
institut
briefli
plate
coat
full
length
mer
spike
protein
block
wash
preand
postimmun
sera
individu
dilut
singl
dilut
incub
c
posit
control
geneon
life
scienc
inc
clinic
protocol
vaccin
nonhuman
primat
sera
neg
control
includ
run
sampl
run
triplic
wash
hrpconjug
antihumanigg
secondari
antibodi
incub
room
temperatur
wash
signal
develop
sigmafast
opd
substrat
stop
valu
read
synergi
micropl
reader
posit
postimmun
sampl
identifi
correspond
cutoff
valu
determin
seroneg
sampl
must
least
sd
preimmun
baselin
sampl
sd
background
control
well
cutoff
valu
set
upper
confid
interv
pool
seroneg
sera
serum
sampl
test
elisa
platform
wistar
insitut
also
evalu
quantit
endpoint
bind
titer
brief
valu
read
synergi
micropl
reader
endpoint
dilut
individu
identifi
reciproc
highest
dilut
correspond
cutoff
valu
determin
seroneg
sampl
must
least
sd
preimmun
baselin
sampl
sd
background
control
well
sampl
test
elisa
wistar
institut
also
evalu
qualit
mer
cov
protein
bind
western
blot
posit
postimmun
sampl
identifi
presenc
antigen
specif
band
expect
kda
size
neutral
antibodi
mer
cov
perform
laboratori
dr
gari
kobing
previous
describ
determin
muthumanni
sci
tran
med
sera
immun
particip
mix
infecti
particl
mer
cov
overlaid
onto
monolay
vero
cell
titer
neutral
antibodi
report
reciproc
highest
dilut
less
cell
show
cytopath
effect
pseudoviru
assay
use
determin
breadth
respons
describ
previous
muthumanni
sci
transl
med
number
antigenspecif
secret
spot
form
unit
sfu
determin
laboratori
dr
david
weiner
elispot
assay
respons
stimul
mer
cov
peptid
use
peptid
overlap
amino
acid
span
entir
protein
genscript
describ
muthumanni
scienc
briefli
pbmc
thaw
plate
cellswel
cell
incub
mer
cov
peptid
incub
overnight
releas
detect
use
standard
procedur
averag
number
sfu
count
media
control
well
subtract
averag
individu
mer
cov
peptid
well
adjust
pbmc
mer
cov
peptid
pool
flow
cytometr
assay
includ
examin
influenc
vaccin
abil
particip
cell
exhibit
phenotyp
marker
associ
cytolyt
potenti
shortterm
stimul
mer
cov
hereaft
refer
ctl
phenotyp
abil
particip
cell
remain
activ
presenc
longterm
antigen
exposur
effici
synthes
protein
use
lytic
activ
hereaft
refer
lytic
granul
load
abil
particip
cell
effect
employ
granzym
b
purpos
lytic
geneon
life
scienc
inc
clinic
protocol
kill
target
cell
express
antigen
hereaft
refer
kill
panel
may
vari
new
inform
becom
avail
ctl
phenotyp
priorit
lytic
granul
load
kill
run
suffici
particip
sampl
present
assay
ctl
phenotyp
employ
vitro
stimul
unfraction
particip
pbmc
use
peptid
span
glycoprotein
describ
along
posit
control
staphylococc
enterotoxin
b
combin
phorbol
ionomycin
ctl
phenotyp
assay
examin
follow
extern
cellular
marker
tcell
identif
memori
subset
identif
marker
lytic
degranul
ctl
phenotyp
assay
addit
analyz
follow
intracellular
marker
interferon
gamma
bias
cytokin
tumor
necrosi
factor
alpha
granzym
granzym
b
perforin
protein
involv
lytic
degranul
cytotox
potenti
marker
evalu
assay
may
chang
new
relev
data
becom
avail
ii
lytic
granul
load
assay
employ
vitro
stimul
unfraction
particip
pmbc
use
peptid
span
mer
protein
irrelev
peptid
control
ova
posit
control
concanavalin
lytic
granul
load
assay
examin
follow
extern
cellular
marker
cell
identif
also
known
marker
cell
activ
lytic
granul
load
assay
addit
analyz
follow
intracellular
marker
granzym
granzym
b
granulysin
perforin
protein
involv
cytotox
potenti
marker
evalu
assay
may
chang
new
relev
data
becom
avail
iii
kill
assay
employ
vitro
stimul
unfraction
pbmc
use
peptid
span
mer
protein
stimul
whole
pbmc
tcell
isol
coincub
minut
target
cell
receiv
stain
differenti
particip
tcell
addit
puls
reagent
activ
upon
cleavag
termin
caspas
target
cell
identifi
use
stain
analyz
presenc
cleav
caspas
activ
target
measur
function
cytolyt
degranul
kill
employ
assay
may
chang
pend
readout
lytic
granul
load
assay
marker
evalu
assay
may
chang
new
relev
data
becom
avail
leukapheresi
provid
mechan
collect
larg
number
leukocyt
better
character
host
immun
without
draw
essenti
fraction
particip
blood
ie
red
blood
cell
clot
factor
leukapheresi
essenti
special
type
plasmapheresi
compon
plasma
drawn
blood
process
storag
white
blood
cell
singl
nuclei
circul
peripher
blood
peripher
blood
mononuclear
cell
collect
cell
interest
leukocyt
procedur
term
leukapheresi
purpos
collect
addit
leukocyt
better
understand
b
cell
immun
phenotyp
dna
rna
sequenc
transcriptom
array
analysi
respons
vaccin
addit
analysi
would
limit
small
volum
blood
draw
week
visit
lieu
peripher
blood
phlebotomi
subset
volunt
option
undergo
apheresi
collect
plasma
pbmc
plasma
leukocyt
geneon
life
scienc
inc
clinic
protocol
plasma
obtain
use
autom
apheresi
techniqu
conduct
qualifi
apheresi
nursetechnician
apheresi
whole
blood
withdrawn
cathet
place
antecubit
vein
channel
cell
separ
cellular
plasma
fraction
separ
centrifug
compon
harvest
ie
leukocyt
direct
collect
bag
erythrocyt
platelet
plasma
compon
interest
eg
immunoglobulin
clot
factor
albumin
return
donor
return
accomplish
second
needl
place
anoth
site
usual
antecubit
vein
approxim
peripher
blood
mononuclear
cell
target
collect
approxim
ml
red
blood
cell
volum
may
lost
residu
loss
machin
procedur
volunt
undergo
leukapheresi
exempt
storag
addit
test
blood
draw
schedul
visit
leukapheresi
perform
particip
platelet
count
hemoglobin
mgdl
part
potenti
exploratori
object
b
lymphocyt
specif
epitop
mer
cov
spike
protein
sort
flow
cytometri
neutral
nonneutr
antibodi
screen
express
resolut
antibodi
structur
complex
protein
may
resolv
nonneutr
antibodi
function
assay
may
includ
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cellmedi
phagocytosi
adcp
antibodydepend
cellmedi
viral
inhibit
adcvi
viral
captur
host
immunegenotyp
perform
resourc
made
avail
investig
perform
target
analys
genet
polymorph
within
host
gene
may
influenc
immun
respons
vaccin
target
gene
involv
humor
cellmedi
immun
respons
includ
receptor
capabl
bind
divers
immunoglobulin
isotyp
allel
compris
class
hlaa
b
c
loci
respect
hla
type
procedur
use
studi
yet
valid
clinic
use
repres
essenti
research
tool
analys
adapt
immun
respons
vaccin
hla
type
data
unlink
person
identifi
report
aggreg
popul
studi
biolog
sampl
serum
plasma
pbmc
whole
blood
store
qualitycontrol
environ
transport
storag
biolog
sampl
handl
accord
glp
standard
futur
use
biolog
sampl
specifi
protocol
requir
addit
irb
review
approv
futur
use
type
research
biolog
sampl
serum
plasma
pbmc
whole
blood
remain
assay
describ
protocol
complet
bar
code
archiv
use
electron
specimen
storag
track
system
pbmc
store
lower
plasmasera
store
lower
sampl
archiv
mhrp
specimen
process
lab
repositori
spl
rockvil
maryland
univers
pennsylvania
specimen
process
laboratori
philadelphia
pennsylvania
indefinit
princip
investig
sponsor
author
regulatori
bodi
may
access
data
regard
archiv
specimen
particip
consid
elig
particip
unless
consent
specimen
store
futur
use
although
result
research
includ
donat
specimen
may
patent
commerci
valu
particip
legal
financi
interest
commerci
develop
result
research
within
hour
follow
studi
treatment
data
download
ep
devic
onto
usb
storag
devic
devic
forward
courier
express
mail
sponsor
geneon
life
scienc
inc
designe
email
instruct
download
data
sponsor
contact
inform
provid
separ
cover
train
also
provid
data
contain
download
code
unidentifi
data
ep
devic
download
monitor
assess
function
error
may
occur
use
inform
includ
imped
measur
voltag
gener
use
qualiti
control
improv
devic
medic
taken
medic
procedur
perform
within
week
prior
enrol
studi
affect
particip
elig
particip
see
section
exclus
criteria
must
record
case
report
form
crf
dosag
frequenc
immunosuppress
medic
also
record
particip
must
vaccin
eg
influenza
vaccin
receiv
polyclon
monoclon
antibodi
within
week
first
dose
week
subsequ
dose
investig
product
particip
must
receiv
cours
system
corticosteroid
mgday
prednison
equival
day
within
week
dose
investig
product
safeti
measur
grade
outlin
appendix
b
throughout
cours
studi
ae
monitor
report
ae
crf
includ
event
serious
sever
action
taken
relationship
studi
drug
ae
occur
first
concern
safeti
studi
particip
ae
must
follow
resolut
stabl
outcom
document
appropri
crf
ae
must
record
standard
medic
terminolog
rather
particip
word
advers
event
ae
defin
unfavor
unintend
chang
structur
function
chemistri
bodi
worsen
preexist
condit
tempor
associ
use
product
whether
consid
relat
use
product
studi
chang
monitor
classifi
summar
clinic
laboratori
ae
medic
conditiondiseas
present
start
investig
drug
consid
advers
event
worsen
start
studi
treatment
unexpect
ae
one
identifi
clinic
investig
brochur
cib
otherwis
expect
characterist
clinic
materi
studi
relat
ae
includ
follow
preor
posttreat
complic
occur
result
protocol
mandat
procedur
screen
administr
studi
drug
preexist
condit
increas
sever
chang
natur
consequ
studi
drug
phase
human
clinic
trial
also
consid
ae
complic
termin
pregnanc
see
section
addit
inform
ae
occur
studi
day
visit
onward
throughout
durat
studi
includ
followup
studi
drug
period
record
ae
perform
condit
lead
procedur
ae
preexist
diseas
condit
laboratori
abnorm
present
detect
first
vaccin
worsen
situat
untoward
medic
occurr
occur
eg
hospit
elect
surgeri
social
andor
conveni
admiss
overdos
without
clinic
sequela
medic
condit
clinic
signific
laboratori
abnorm
onset
date
first
vaccin
relat
protocol
associ
procedur
ae
consid
preexist
document
medic
histori
crf
uncompl
pregnanc
induc
elect
abort
termin
pregnanc
without
medic
reason
seriou
advers
event
sae
ae
meet
one
follow
condit
death
period
surveil
defin
protocol
immedi
lifethreaten
eg
particip
view
investig
immedi
risk
death
event
occur
includ
ae
occur
seriou
form
might
caus
death
event
requir
particip
hospit
prolong
exist
hospit
period
protocol
defin
surveil
includ
overnight
stay
hospit
regardless
length
stay
even
hospit
precautionari
measur
allow
continu
observ
howev
hospit
includ
hospit
elect
procedur
continu
treatment
assess
preexist
condit
worsen
constitut
sae
evalu
nonadmit
statu
overnight
overday
observ
emerg
depart
urgent
care
set
offic
set
constitut
sae
result
congenit
anomali
birth
defect
result
persist
signific
disabilityincapac
substanti
disrupt
abil
conduct
normal
life
function
import
medic
event
may
result
death
life
threaten
requir
hospit
base
upon
appropri
medic
judgment
may
jeopard
particip
may
requir
medic
surgic
intervent
prevent
one
outcom
list
exampl
medic
event
includ
allerg
bronchospasm
requir
intens
treatment
emerg
room
home
blood
dyscrasia
convuls
result
particip
hospit
develop
drug
depend
drug
abus
develop
malign
medic
signific
requir
intervent
prevent
one
outcom
list
death
outcom
ae
advers
event
particip
may
investig
medicin
product
occurr
event
dose
may
given
treatment
cycl
interrupt
temporarili
onset
sae
may
contribut
event
inpati
hospit
mean
particip
formal
admit
hospit
medic
reason
length
time
may
may
overnight
observ
statu
evalu
emerg
depart
urgent
care
set
outpati
offic
constitut
sae
investig
attempt
establish
diagnosi
event
basi
sign
symptom
andor
clinic
inform
case
diagnosi
document
ae
andor
sae
individu
signssymptom
seriou
advers
event
ongo
follow
resolut
report
period
sae
describ
section
medic
attend
advers
event
maae
defin
advers
event
lead
unplan
contact
health
care
provid
unexpect
advers
drug
reaction
adr
reaction
natur
sever
consist
applic
product
inform
investig
brochur
product
inform
amend
expedit
report
requir
addit
occurr
reaction
report
add
signific
inform
specif
sever
known
alreadi
document
sae
constitut
unexpect
event
exampl
event
specif
sever
describ
investig
brochur
would
consid
unexpect
specif
exampl
would
acut
renal
failur
label
adr
subsequ
new
report
interstiti
nephriti
b
hepat
first
report
fulmin
hepat
unexpect
advers
devic
event
uad
seriou
advers
effect
health
safeti
lifethreaten
problem
death
caus
associ
devic
effect
problem
death
previous
identifi
natur
sever
degre
incid
investig
plan
applic
unanticip
seriou
problem
associ
devic
relat
right
safeti
welfar
subject
report
uad
sent
sponsor
within
work
day
becom
awar
event
uad
report
wrair
irb
expedit
report
note
section
investig
grade
laboratori
ae
clinic
ae
base
discuss
studi
particip
outlin
appendix
b
mild
grade
advers
event
captur
crf
maximum
sever
report
causal
relat
ae
one
judg
suspect
relationship
administr
clinic
materi
investig
cellectra
devic
ae
may
also
assess
relat
investig
product
princip
investig
assist
dod
research
monitor
need
respons
report
advers
event
judg
relationship
administr
clinic
materi
subsequ
ae
investig
knowledg
particip
eg
medic
histori
concomit
medic
administ
investig
product
monitor
particip
respons
investig
product
investig
awar
particip
clinic
state
thu
may
sensit
distinct
event
due
underli
diseas
process
versu
event
may
product
relat
may
observ
event
sponsor
assess
overal
safeti
investig
product
determin
whether
report
expediti
regulatori
agenc
investig
must
assign
relationship
ae
receipt
investig
product
investig
use
clinic
judgment
conjunct
assess
plausibl
biolog
mechan
tempor
relationship
onset
event
relat
receipt
investig
product
identif
possibl
altern
etiolog
includ
underli
diseas
concurr
ill
concomit
medic
follow
guidelin
use
investig
assess
relationship
ae
studi
product
administr
physician
make
determin
relationship
investig
product
appli
event
evid
exist
altern
etiolog
unlik
like
unrel
investig
product
like
relat
factor
investig
product
rule
certainti
possibl
associ
event
administr
investig
product
rule
reason
tempor
associ
may
also
altern
etiolog
subject
clinic
statu
underli
factor
includ
therapi
probabl
high
degre
certainti
relationship
investig
product
exist
reason
tempor
associ
event
explain
known
characterist
subject
clinic
state
factor
includ
therapi
definit
associ
exist
receipt
investig
product
event
associ
factor
rule
laboratori
physic
exam
ekg
abnorm
usual
record
ae
sae
howev
clinic
ekg
laboratori
abnorm
eg
serum
chemistri
cbc
cpk
independ
underli
medic
condit
requir
medic
surgic
intervent
lead
investig
medicin
product
interrupt
discontinu
must
record
ae
well
sae
applic
addit
laboratori
abnorm
assess
eg
electrocardiogram
xray
vital
sign
associ
sign
andor
symptom
must
geneon
life
scienc
inc
clinic
protocol
ae
sae
meet
definit
ae
sae
describ
section
laboratori
abnorm
part
syndrom
record
syndrom
diagnosi
eg
anemia
laboratori
result
eg
decreas
hemoglobin
laboratori
abnorm
new
onset
worsen
sever
frequenc
baselin
condit
meet
one
follow
criteria
record
ae
requir
therapeut
intervent
diagnost
test
lead
discontinu
studi
treatment
accompani
induc
symptom
sign
judg
investig
clinic
signific
sever
assess
detail
section
abnorm
deem
princip
investig
clinic
signific
stabl
follow
thereaft
particip
pregnant
expect
becom
pregnant
cours
studi
exclud
particip
studi
particip
becom
pregnant
enrol
studi
given
treatment
princip
investig
report
event
studi
team
medic
monitor
designe
irb
site
must
request
particip
permiss
queri
pregnanc
outcom
follow
particip
determin
outcom
pregnanc
result
summar
clinic
studi
report
csr
particip
becom
pregnant
point
studi
continu
follow
safeti
assess
without
receiv
investig
product
data
sampl
collect
prior
particip
withdraw
consent
includ
data
analysi
unless
otherwis
specifi
particip
procedur
contraind
pregnanc
includ
addit
treatment
must
perform
investig
use
clinic
judgment
regard
subsequ
studyrel
blood
collect
base
presenc
absenc
anemia
particip
particip
withdrawn
continu
follow
safeti
assess
studi
discharg
per
protocol
pregnanc
occur
time
first
screen
procedur
follow
visit
must
report
monitor
particip
outcom
pregnanc
follow
investig
end
pregnanc
occur
studi
complet
outcom
report
directli
studi
team
medic
monitor
male
particip
instruct
inform
consent
form
immedi
inform
investig
partner
becom
pregnant
end
followup
period
pregnanc
form
complet
investig
submit
sponsor
within
hour
learn
pregnanc
attempt
made
collect
report
detail
cours
outcom
pregnanc
partner
male
particip
expos
studi
treatment
pregnant
partner
need
sign
author
use
disclosur
pregnanc
health
inform
allow
followup
pregnanc
author
sign
investig
updat
pregnanc
form
addit
inform
cours
outcom
pregnanc
investig
contact
male
particip
pregnant
partner
may
provid
inform
risk
pregnanc
possibl
effect
fetu
support
inform
decis
cooper
treat
physician
andor
obstetrician
ae
sae
includ
death
regardless
caus
relationship
must
report
particip
studi
includ
protocolrequir
posttreat
followup
investig
oblig
activ
seek
ae
sae
beyond
follow
period
particip
howev
investig
learn
ae
sae
occur
complet
termin
visit
event
deem
investig
probabl
possibl
relat
studi
treatment
hesh
promptli
document
report
event
studi
team
medic
monitor
day
dose
studi
particip
directli
observ
studi
personnel
minimum
minut
inject
contact
studi
personnel
day
post
vaccin
immedi
reaction
occurr
sever
ae
period
lack
record
appropri
crf
particip
given
oral
thermomet
particip
remind
diari
ask
take
record
oral
temperatur
daili
time
note
character
word
local
system
ae
experi
day
period
injectionep
procedur
throughout
studi
addit
daili
record
oral
temperatur
inject
site
reaction
system
complaint
record
day
inject
clinic
materi
studi
particip
queri
clinic
visit
regard
occurr
sae
unexpect
ae
may
occur
sinc
last
visit
remind
contact
studi
personnel
immedi
report
event
happen
cours
studi
event
record
crf
ae
regardless
sever
serious
presum
relationship
studi
treatment
must
record
use
medic
terminolog
sourc
document
crf
whenev
possibl
diagnosi
document
lieu
symptom
sourc
document
crf
must
contain
investig
opinion
concern
relationship
ae
studi
treatment
ae
describ
follow
attribut
durat
start
end
date
serious
sever
causal
action
taken
outcom
medic
monitor
respons
overal
safeti
monitor
studi
site
pi
dod
safeti
monitor
respons
local
safeti
incid
advers
event
classifi
system
organ
class
soc
prefer
term
sever
relationship
studi
treatment
chang
safeti
laboratori
paramet
eg
hematolog
serum
chemistri
urinalysi
local
system
inject
site
review
special
attent
paid
examin
inject
site
administr
site
reaction
particip
complaint
document
event
requir
expedit
report
erer
defin
advers
event
special
interest
see
section
regardless
intens
relationship
studi
treatment
studi
treatmentrel
advers
event
follow
grade
greater
administr
site
erythema
andor
indur
record
hour
studi
treatment
grade
greater
administr
site
pain
tender
record
hour
studi
treatment
grade
greater
fever
grade
greater
system
symptom
includ
gener
pruritu
grade
greater
laboratori
abnorm
unexpect
advers
devic
event
per
toxic
grade
healthi
adult
appendix
b
sever
grade
particular
event
document
crf
site
inform
sponsor
erer
within
hour
discuss
whether
dose
particip
continu
follow
situat
occur
enrol
studi
treatment
halt
immedi
thorough
investig
conduct
dod
research
monitor
princip
investig
irbec
applic
three
particip
per
dose
level
experi
erer
assess
relat
studi
treatment
three
particip
treatment
arm
discontinu
due
ae
relat
studi
treatment
includ
particip
discontinu
due
pain
relat
ep
procedur
particip
experi
sae
eg
potenti
life
threaten
ae
grade
ae
death
assess
relat
studi
treatment
two
particip
within
treatment
arm
experi
similar
grade
advers
event
assess
relat
studi
treatment
seven
particip
across
treatment
arm
experi
similar
grade
advers
event
assess
relat
studi
treatment
report
anaphylaxi
assess
relat
studi
treatment
related
studi
treatment
consid
possibl
probabl
definit
determin
pi
immedi
pain
ip
consid
stop
criteria
upon
conclus
sponsor
designe
notifi
investig
irbsec
requir
regard
outcom
investig
stem
studi
paus
sae
death
assess
relat
studi
treatment
lead
immedi
halt
studi
enrol
studi
treatment
guidelin
assess
related
detail
section
manag
carri
wrair
one
repres
data
collect
conduct
tablet
comput
daili
upload
central
databas
access
data
collect
softwar
limit
individu
usernam
password
data
store
encrypt
fashion
local
comput
data
upload
central
databas
delet
local
tablet
comput
data
obtain
conduct
studi
hous
secur
databas
maintain
wrair
andor
repres
research
data
enter
secur
databas
standard
qualiti
assur
review
procedur
accord
good
clinic
practic
gcp
data
enter
maintain
passwordprotect
databas
data
access
clinic
data
manag
sponsor
inform
technolog
staff
author
work
protocol
databas
locat
wrair
ctc
andor
repres
protect
firewal
data
contain
particip
name
social
secur
nation
identif
number
referenc
studi
specif
identif
code
subject
consent
assign
particip
identif
number
pid
first
three
digit
protocol
number
follow
number
assign
sequenti
everi
attempt
must
made
follow
protocol
obtain
record
data
request
subject
specifi
time
howev
ethic
consider
event
may
result
failur
obtain
record
certain
data
record
data
time
specifi
occur
event
reason
event
must
clearli
document
case
report
form
deviat
report
describ
analysi
file
creat
period
basi
made
avail
princip
investig
associ
investig
ai
medic
monitor
direct
princip
investig
collabor
may
given
access
analysi
file
data
gather
direct
princip
investig
data
may
made
avail
list
extern
file
queri
program
statist
analysi
data
perform
wrair
repres
descript
statist
present
data
collect
phase
studi
perprotocol
pp
analysi
compris
particip
receiv
vaccin
dose
protocol
deviat
defin
primari
endpoint
data
avail
particip
sampl
group
treatment
arm
assign
modifi
intent
treat
mitt
analysi
includ
particip
receiv
least
one
studi
treatment
particip
ampl
group
treatment
arm
assign
analys
mitt
sampl
consid
support
correspond
pp
analys
safeti
analysi
set
includ
particip
receiv
least
one
studi
treatment
postdos
safeti
data
avail
particip
analyz
treatment
receiv
particip
complet
studi
replac
demograph
baselin
data
vital
sign
medic
histori
concomit
ill
current
medicationstreat
summar
mean
descript
statist
mean
standard
deviat
minimum
median
maximum
valu
continu
variabl
percentag
categor
variabl
stratifi
treatment
arm
data
enrol
particip
analyz
accord
initi
assign
regardless
mani
vaccin
receiv
analysi
modifi
intenttotreat
analysi
individu
screen
enrol
contribut
data
henc
exclud
solicit
unsolicit
ae
summar
frequenc
per
treatment
arm
frequenc
present
separ
dose
overal
ie
base
pool
dose
depict
overal
system
organ
class
prefer
term
number
percentag
particip
affect
percentag
along
associ
clopperpearson
confid
interv
base
number
particip
treat
addit
frequenc
present
respect
maximum
sever
strongest
relationship
studi
treatment
multipl
occurr
ae
count
follow
worstcas
approach
respect
sever
relationship
studi
treatment
seriou
ae
administr
site
event
also
summar
main
summari
safeti
data
base
event
occur
within
day
administr
studi
treatment
specifi
section
continu
respons
variabl
per
time
point
chang
baselin
summar
mean
median
minimum
maximum
valu
categor
respons
variabl
summar
per
time
point
percentag
calcul
accord
treatment
arm
data
classifi
positiveneg
respondernonrespond
analyz
frequenc
respons
assay
within
treatment
arm
time
point
assess
perform
proport
respond
present
correspond
ci
estim
base
clopperpearson
methodolog
continu
variabl
eg
neutral
bind
antibodi
titer
analyz
assay
within
treatment
arm
mean
valu
correspond
ci
estim
base
distribut
formal
power
analysi
applic
studi
descript
statist
use
summar
data
particip
per
treatment
arm
studi
provid
confid
true
incid
sae
sae
observ
treatment
arm
overal
treat
particip
studi
provid
confid
true
incid
sae
sae
observ
miss
data
replac
calcul
done
report
valu
interim
analysi
carri
prior
databas
lock
monitor
data
accord
formal
statist
analysi
plan
develop
princip
investig
data
geneon
life
scienc
inc
clinic
protocol
analysi
team
brief
interim
analysi
carri
enrol
studi
particip
focu
primarili
safeti
reactogen
immunogen
data
primari
analysi
evalu
baselin
demograph
advers
event
outcom
aggreg
across
three
differ
dose
group
reactogen
longer
term
advers
event
endpoint
compar
across
group
primari
immunogen
endpoint
evalu
comparison
across
three
dose
group
endpoint
antibodi
bind
titer
spike
protein
viru
neutral
antibodi
titer
week
visit
interim
analysi
also
comparison
carri
neutral
bind
antibodi
titer
curv
across
time
point
week
cellular
immunolog
outcom
assess
final
analysi
individu
data
releas
analys
impact
cours
studi
though
may
publish
use
plan
futur
studi
safeti
analys
may
includ
enrol
demograph
inform
medic
histori
concomit
medic
physic
assess
protocol
adher
clinic
laboratori
valu
solicit
unsolicit
advers
event
inform
studi
particip
kept
confidenti
best
studi
site
abil
event
particip
revok
author
collect
use
phi
sponsor
retain
abil
use
inform
collect
prior
revoc
particip
author
particip
revok
author
collect
use
phi
attempt
made
obtain
permiss
collect
least
vital
statu
ie
particip
aliv
end
schedul
studi
period
nonexempt
research
involv
human
subject
shall
minimum
meet
requir
cfr
particip
injur
particip
research
dod
healthcar
beneficiari
eg
activ
duti
militari
militari
spous
depend
particip
entitl
medic
care
injuri
within
dod
healthcar
system
long
particip
remain
dod
healthcar
beneficiari
care
includ
limit
free
medic
care
militari
hospit
clinic
particip
injur
particip
research
dod
healthcar
beneficiari
particip
entitl
medic
care
injuri
militari
hospit
clinic
medic
care
charg
care
militari
hospit
clinic
waiv
determin
advanc
militari
hospit
clinic
provid
care
particip
obtain
care
researchrel
injuri
outsid
militari
hospit
clinic
particip
particip
insur
respons
medic
expens
particip
transport
dod
hospit
clinic
provid
except
emerg
situat
nondod
health
care
beneficiari
requir
militari
escort
access
said
hospit
clinic
sourc
data
inform
origin
record
clinic
find
observ
activ
clinic
trial
necessari
reconstruct
evalu
trial
sourc
data
contain
origin
sourc
document
exampl
origin
document
data
record
includ
hospit
record
clinic
offic
chart
laboratori
note
memoranda
particip
diari
evalu
checklist
pharmaci
dispens
record
record
data
autom
instrument
copi
transcript
certifi
verif
accur
complet
microfich
photograph
neg
microfilm
magnet
media
xray
particip
file
record
kept
pharmaci
laboratori
medic
record
within
inform
technolog
system
involv
clinic
trial
monitor
clinic
trial
perform
experienc
monitor
report
sponsor
sponsor
designe
record
clinic
particip
trial
monitor
follow
clinic
site
monitor
task
perform
site
crf
provid
studi
particip
particip
must
identifi
name
crf
particip
identifi
particip
identif
number
pid
sponsor
respons
retain
studi
essenti
document
least
year
last
approv
market
applic
countri
pend
contempl
market
applic
countri
least
year
elaps
sinc
formal
discontinu
clinic
develop
investig
product
sponsor
inform
investigatorinstitut
document
longer
need
retain
monitor
monitor
clinic
trial
perform
experienc
monitor
report
sponsor
sponsor
designe
record
clinic
particip
trial
monitor
follow
clinic
site
monitor
task
perform
site
prior
trial
initi
site
visit
conduct
review
relev
form
document
ensur
complianc
applic
requir
clinic
site
monitor
visit
document
period
site
visit
perform
throughout
studi
site
monitor
respons
address
document
follow
studi
conduct
activ
oblig
assur
studi
conduct
accord
protocol
applic
regulatori
agenc
regul
irbec
polici
discuss
studi
conduct
issu
incid
noncompli
investig
andor
studi
personnel
document
resolut
trip
report
report
signific
unresolv
problem
immedi
sponsor
remind
investig
necessari
oblig
immedi
report
seriou
advers
event
sae
provid
subsequ
followup
report
final
outcom
irbec
inspect
case
report
form
crf
page
complet
logic
intern
consist
throughout
studi
assur
studi
facil
continu
accept
compar
studi
crf
sourc
document
assur
data
accur
complet
protocol
follow
assur
test
articl
account
reconcili
record
complet
accur
geneon
life
scienc
inc
clinic
protocol
assur
particip
specimen
store
forward
properli
test
record
avail
audit
investig
make
studi
document
eg
icf
drug
account
form
crf
pertin
hospit
clinic
record
readili
avail
inspect
local
irbec
repres
depart
defens
site
monitor
regulatori
agenc
geneon
life
scienc
inc
designe
confirm
studi
data
particip
investig
studi
impli
accept
potenti
inspect
regulatori
author
applic
complianc
qualiti
assur
offic
assur
safeti
particip
inform
ae
see
section
safeti
paramet
definit
whether
volunt
particip
discov
investig
studi
staff
question
detect
physic
examin
laboratori
test
mean
collect
record
particip
sourc
document
follow
appropri
addit
ae
report
summari
studi
overal
progress
forward
regulatori
agenc
accord
local
requir
eg
everi
month
annual
solicit
unsolicit
advers
event
collect
throughout
studi
record
crf
studi
report
analyz
summar
advers
event
throughout
studi
unsolicit
ae
summar
day
period
follow
administr
studi
treatment
see
next
section
sae
advers
event
summar
time
continu
review
report
period
sae
without
regard
causal
entir
period
follow
sign
inform
consent
form
end
studi
ae
assess
determin
whether
meet
serious
criteria
ae
consid
seriou
investig
record
event
geneon
life
scienc
within
hour
becom
awar
event
investig
may
also
directli
report
event
wrair
irb
per
standard
oper
procedur
within
hour
expected
sae
determin
geneon
life
scienc
use
refer
safeti
inform
specifi
investig
brochur
event
may
qualifi
expedit
report
regulatori
author
sae
unexpect
per
refer
safeti
inform
consid
relat
follow
guidelin
section
seriou
unexpect
suspect
advers
reaction
susar
line
relev
legisl
investig
receiv
safeti
letter
notifi
relev
susar
report
investig
notifi
ethic
committe
soon
practic
seriou
event
write
requir
local
regulatori
author
accord
local
institut
polici
time
complet
sae
report
period
investig
becom
awar
sae
suspect
investig
relat
studi
drug
event
report
sponsor
designe
report
contain
much
clinic
safeti
inform
possibl
minimum
initi
report
must
includ
follow
inform
event
studi
code
particip
number
date
birth
investig
studi
product
report
name
contact
inform
case
minimum
report
one
sole
compris
inform
bullet
detail
followup
report
sent
soon
inform
becom
avail
later
calendar
day
date
initi
report
sae
must
follow
resolut
stabil
report
death
investig
suppli
geneon
life
scienc
ethic
committe
addit
request
inform
eg
autopsi
report
termin
medic
report
addit
report
death
occur
realtim
origin
sae
form
must
kept
studi
site
geneon
life
scienc
repres
respons
determin
turn
report
sae
regulatori
author
accord
applic
regulatori
requir
sae
must
follow
investig
resolut
even
extend
beyond
studyreport
period
resolut
sae
defin
return
baselin
statu
stabil
condit
expect
remain
chronic
accord
local
regul
sponsor
shall
notifi
appropri
regulatori
author
particip
investig
written
safeti
report
advers
experi
associ
use
product
seriou
unexpect
eg
fda
form
us
report
seriou
advers
event
shall
made
soon
possibl
event
later
calendar
day
sponsor
initi
receipt
inform
written
notif
may
submit
form
describ
equival
narr
format
shall
bear
promin
identif
content
written
notif
regulatori
agenc
shall
transmit
divis
respons
review
written
safeti
report
sponsor
shall
identifi
safeti
report
previous
file
concern
similar
advers
experi
shall
analyz
signific
advers
experi
light
previou
similar
report
sponsor
shall
also
notifi
relev
regulatori
author
telephon
facsimil
transmiss
death
regardless
causal
unexpect
fatal
lifethreaten
experi
associ
use
drug
soon
possibl
event
later
calendar
day
sponsor
initi
receipt
inform
telephon
call
facsimil
transmiss
regulatori
agenc
shall
transmit
divis
respons
review
follow
inform
safeti
report
shall
submit
soon
relev
inform
avail
result
sponsor
event
investig
show
advers
drug
experi
initi
determin
report
fact
report
sponsor
shall
report
experi
written
safeti
report
soon
possibl
event
later
calendar
day
geneon
life
scienc
inc
clinic
protocol
made
result
investig
safeti
inform
shall
submit
appropri
inform
amend
annual
report
addit
report
period
sae
specifi
section
investig
becom
awar
sae
assess
relat
investig
product
follow
guidelin
section
occur
within
day
stop
investig
product
sae
must
report
accord
procedur
specifi
protocol
event
death
autopsi
perform
copi
report
sent
geneon
life
scienc
inc
maae
collect
entir
studi
one
year
follow
last
studi
treatment
report
period
maae
entir
period
follow
sign
inform
consent
form
studi
discharg
tabul
maae
assess
relationship
studi
treatment
includ
requir
period
report
regulatori
agenc
problem
experienc
treatment
procedur
includ
potenti
malfunct
cellectra
devic
error
messag
display
devic
screen
follow
treatment
error
occur
treatment
procedur
must
report
sponsor
designe
immedi
evalu
error
report
form
provid
appendix
must
complet
email
sponsor
error
geneonelsuscom
inovio
pharmaceut
eperror
inoviocom
geneon
life
scienc
reserv
right
discontinu
studi
site
multipl
site
safeti
administr
reason
time
particular
site
recruit
reason
rate
may
discontinu
studi
termin
andor
site
close
whatev
reason
document
studi
product
pertain
studi
must
return
geneon
life
scienc
repres
protocol
deviat
defin
isol
occurr
involv
procedur
follow
studi
protocol
timelin
report
protocol
deviat
divis
human
subject
protect
wrair
irb
determin
categor
deviat
emergentsignific
nonemergentminor
unanticip
problem
report
appropri
timefram
accord
serious
event
signific
deviat
minor
deviat
emergentsignific
deviat
departur
protocol
signific
impact
welfar
safeti
volunt
integr
studi
data
exampl
provid
wrong
lab
result
volunt
failur
obtain
schedul
blood
draw
multipl
particip
chang
protocol
procedur
may
initi
without
prior
irbeth
review
committe
approv
case
chang
necessari
elimin
immedi
appar
hazard
nonemergentminor
deviat
routin
departur
typic
involv
volunt
failur
compli
protocol
exampl
includ
miss
schedul
visit
fail
complet
requir
questionnair
minor
deviat
report
sponsor
divis
geneon
life
scienc
inc
clinic
protocol
subject
protectionirb
summari
report
annual
continu
review
report
cumul
deviat
report
submit
hspbwrair
irb
protocol
continu
review
report
closeout
report
whichev
come
first
major
protocol
deviat
advers
affect
safeti
right
particip
scientif
integr
studi
report
wrair
hspb
within
hour
written
report
submit
within
work
day
contact
inform
wrair
hspb
follow
director
human
subject
protect
branch
robert
grant
avenu
silver
spring
md
telephon
fax
email
usarmydetrickmedcomwrairmbxhspb
mailmil
protocol
deviat
occur
within
report
period
summar
continu
review
report
submit
wrair
hspb
modif
protocol
support
document
inform
consent
ssp
sop
recruit
materi
etc
must
review
approv
prior
implement
protocol
amend
agre
upon
approv
sponsor
repres
prior
submiss
wrair
irb
prior
implement
said
chang
modif
inform
consent
document
must
revis
concur
amend
appropri
must
review
approv
amend
subject
alreadi
enrol
studi
inform
revis
ask
sign
revis
inform
consent
document
modif
directli
affect
individu
particip
studi
copi
revis
sign
date
inform
consent
document
given
subject
origin
version
inform
consent
document
retain
protocol
regulatori
file
modif
could
potenti
increas
risk
subject
must
submit
orp
hrpo
fda
approv
prior
implement
document
wrair
irb
review
approv
modif
also
submit
polici
usamrmc
data
sheet
complet
particip
particip
research
form
volunt
registri
data
sheet
data
sheet
enter
command
volunt
registri
databas
inform
enter
confidenti
data
base
includ
particip
name
address
social
secur
number
studi
titl
date
particip
intent
data
base
twofold
first
readili
answer
question
concern
individu
particip
research
sponsor
usamrmc
second
ensur
usamrmc
exercis
oblig
ensur
research
particip
adequ
warn
duti
warn
risk
provid
new
inform
becom
avail
inform
store
usamrmc
minimum
year
volunt
registri
databas
separ
entiti
link
studi
databas
public
result
trial
allow
propos
present
abstract
andor
manuscript
must
made
avail
geneon
life
scienc
inc
day
prior
submiss
public
geneon
life
scienc
inc
shall
thirti
day
receipt
copi
object
propos
present
public
patent
particip
matter
need
protect
event
geneon
life
scienc
inc
make
object
research
shall
refrain
make
public
present
maximum
three
month
date
receipt
object
order
patent
applic
direct
patent
particip
matter
contain
propos
public
present
file
unit
state
patent
trademark
offic
andor
foreign
patent
offic
data
collect
studi
use
support
ind
serum
whole
blood
follow
inform
must
includ
label
immunolog
sampl
drawn
allow
accur
process
analysi
sampl
research
monitor
function
independ
safeti
advoc
particip
per
dod
instruct
research
monitor
requir
review
unanticip
problem
involv
risk
particip
other
seriou
advers
event
sae
report
particip
death
research
monitor
provid
unbias
written
report
unanticip
problem
involv
risk
particip
other
relat
sae
death
within
work
day
wrair
irb
email
usarmydetrickmedcomwrairmbxhspb
mailmil
mail
follow
address
walter
reed
armi
institut
research
attn
human
subject
protect
branch
robert
grant
ave
silver
spring
md
addit
submiss
dod
research
monitor
report
wrair
irb
copi
report
sent
sponsor
team
research
monitor
report
unrel
sae
death
kept
correspond
sae
report
studi
site
wrair
hspb
submit
copi
report
usamrmc
orp
hrpo
per
sop
dod
research
monitor
minimum
must
comment
outcom
event
problem
case
seriou
advers
event
death
comment
relationship
particip
studi
monitor
must
also
indic
whether
hesh
concur
detail
report
provid
princip
investig
dod
research
monitor
review
initi
report
sae
unanticip
problem
involv
risk
particip
other
particip
death
time
manner
provid
independ
report
unanticip
problem
involv
risk
particip
other
encompass
broader
categori
event
sae
may
includ
issu
problem
loss
control
particip
data
investig
product
advers
psycholog
reaction
breach
confidenti
risk
other
eg
program
personnel
must
also
report
unanticip
problem
involv
risk
particip
other
incid
experi
outcom
meet
follow
criteria
unexpect
term
natur
sever
frequenc
given
procedur
describ
protocol
investig
brochur
inform
consent
document
b
characterist
particip
popul
relat
possibl
relat
particip
particip
studi
suggest
studi
place
particip
other
greater
risk
harm
previous
known
recogn
unanticip
problem
involv
risk
particip
other
promptli
report
hour
telephon
email
fax
wrair
hspb
complet
written
report
follow
initi
notif
within
work
day
unanticip
problem
occur
within
report
period
also
summar
continu
review
report
submit
wrair
hspb
contact
inform
wrair
hspb
follow
director
human
subject
protect
branch
robert
grant
avenu
silver
spring
md
telephon
fax
email
usarmydetrickmedcomwrairmbxhspb
mailmil
relat
seriou
advers
event
sae
death
report
wrair
hspb
within
hour
telephon
email
fax
complet
written
report
follow
initi
notif
within
work
day
sae
occur
within
report
period
also
summar
continu
review
report
submit
wrair
hspb
contact
inform
wrair
hspb
follow
amendmentsmodif
protocol
support
document
inform
consent
ssp
sop
recruit
materi
etc
must
review
wrair
hspb
wrair
command
author
approv
issu
prior
wrair
particip
amendedmodifi
protocol
wrair
point
contact
respons
prepar
submit
continu
review
report
per
closeout
report
per
wrair
polici
wrair
hspb
review
acknowledg
report
order
wrair
personnel
continu
particip
studi
studi
activ
complet
includ
data
analysi
closeout
report
need
submit
wrair
hspb
close
studi
knowledg
pend
complianc
inspectionvisit
fda
offic
human
research
protect
depart
health
human
servic
govern
agenc
concern
clinic
investig
research
issuanc
inspect
report
fda
form
warn
letter
action
taken
regulatori
agenc
includ
legal
medic
action
instanc
seriou
continu
noncompli
regul
requir
report
immedi
wrair
hspb
review
sever
advers
event
seriou
advers
event
protocol
violat
annual
report
may
perform
oversight
function
eg
observ
recruit
enrol
procedur
consent
process
individu
group
unit
overse
studi
intervent
interact
review
monitor
plan
upirtso
report
overse
data
match
data
collect
analysi
may
discuss
research
protocol
investig
interview
human
subject
consult
other
outsid
studi
research
author
stop
research
protocol
progress
remov
individu
human
subject
research
protocol
take
whatev
step
necessari
protect
safeti
wellb
human
subject
irb
assess
monitor
report
geneon
life
scienc
inc
clinic
protocol
act
independ
parti
avail
help
answer
question
imparti
standpoint
compli
gcp
belmont
principl
qualifi
train
educ
experi
ensur
accuraci
qualiti
integr
data
perform
meddra
code
review
electron
case
report
form
ecrf
consist
clariti
gener
resolv
data
queri
provid
analysi
feedback
pi
protocol
nurs
coordin
protocol
team
run
discrep
report
qualiti
control
check
report
distribut
protocol
nurs
coordin
review
data
accuraci
ecrf
overse
data
entri
process
studi
particip
receiv
financi
compens
visit
time
effort
involv
particip
studi
compens
follow
screen
visit
visit
follow
phone
call
per
vaccin
plu
per
schedul
follow
studi
visit
bonu
complet
inject
schedul
visit
week
complet
last
schedul
studi
visit
chosen
leukapheresi
compens
visit
visit
addit
follow
regul
activ
duti
personnel
feder
employe
compens
visit
blood
draw
occur
per
visit
unless
visit
occur
offduti
hour
leav
volunt
offduti
leav
paid
nonmilitarynonfeder
personnel
total
amount
compens
may
vari
depend
number
visit
complet
civilian
nonfeder
employe
volunt
undergo
inject
may
receiv
approxim
compens
particip
activ
duti
feder
employe
part
vaccin
group
expect
receiv
approxim
compens
unless
approv
leav
particip
outsid
normal
duti
hour
statist
analysi
plan
sap
phase
openlabel
doserang
studi
evalu
safeti
toler
immunogen
administ
intramuscularli
im
follow
electropor
ep
healthi
volunt
describ
expand
upon
statist
inform
present
protocol
document
describ
plan
analys
provid
reason
justif
analys
also
includ
sampl
tabl
list
figur
plan
final
analys
regard
final
analys
clinic
studi
report
csr
sap
follow
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
ich
guidelin
indic
topic
structur
content
clinic
studi
report
gener
consist
topic
gener
consider
clinic
trial
topic
statist
principl
clinic
trial
structur
content
sap
provid
suffici
detail
meet
requir
identifi
fda
ich
work
plan
report
sap
follow
intern
accept
guidelin
publish
american
statist
associ
royal
statist
societi
statist
practic
document
contain
four
section
review
studi
design
gener
statist
consider
comprehens
statist
analysi
method
immunogen
safeti
outcom
list
propos
tabl
figur
deviat
sap
describ
justifi
protocol
amend
andor
csr
appropri
reader
sap
encourag
also
review
studi
protocol
detail
conduct
studi
oper
aspect
clinic
assess
introduct
phase
openlabel
dose
rang
studi
evalu
safeti
toler
immunogen
contain
plasmid
encod
consensu
sequenc
spike
protein
middl
eastern
respiratori
syndrom
coronaviru
mer
cov
current
approv
treatment
prophylact
vaccin
mer
cov
although
number
product
pois
advanc
human
trial
tcell
respons
follow
vaccin
determin
effect
vaccin
followup
determin
longev
immunogen
analys
assess
safeti
toler
immunogen
includ
clinic
studi
report
note
analys
endpoint
includ
protocol
detail
plan
see
section
detail
regard
exploratori
endpoint
analys
includ
sap
furthermor
interim
safeti
monitor
assess
requir
enrol
next
dose
level
conduct
throughout
studi
includ
sap
addit
analysi
leukapheresi
substudi
also
includ
sap
interim
analys
assess
safeti
immunogen
week
visit
also
includ
sap
evalu
safeti
toler
administ
im
inject
follow
ep
healthi
adult
particip
evalu
cellular
humor
respons
deliv
im
follow
ep
evalu
dose
respons
cellular
humor
reactiv
deliv
im
follow
ep
explor
whether
end
point
antibodi
titer
mer
cov
protein
dose
relat
explor
time
onset
antibodi
product
longev
serolog
respons
explor
increas
dose
level
rapidli
induc
cellular
immun
explor
time
onset
cell
respons
longev
cell
mediat
immun
evalu
kinet
antigen
express
peripher
blood
compart
evalu
host
genet
potenti
predictor
vaccin
immun
respons
evalu
addit
cellular
immun
respons
neutral
nonneutr
antibodi
repertoir
analysi
explor
innat
immun
respons
mer
cov
protein
assess
crossneutr
activ
human
coronavirus
incid
advers
event
classifi
system
organ
class
soc
prefer
term
pt
sever
relationship
studi
treatment
schedul
administr
inject
site
reaction
describ
frequenc
sever
grade
administr
site
pain
chang
safeti
laboratori
paramet
describ
frequenc
sever
grade
eg
liver
panel
test
vital
sign
quantit
bind
antibodi
titer
full
length
mer
cov
spike
glycoprotein
qualit
quantit
level
neutral
antibodi
mer
cov
antigen
specif
cellular
immun
respons
mer
cov
determin
studi
treatment
procedur
consist
insert
cellectra
electropor
array
needl
electrod
skin
underli
muscl
intramuscular
studi
vaccin
follow
deliveri
electropor
puls
procedur
broadli
describ
administr
involv
inject
drug
purpos
defin
analysi
popul
complianc
measur
treatment
administr
protocol
includ
vaccin
dose
im
inject
well
follow
ep
administr
success
treatment
administr
requir
vaccin
dose
ep
administ
success
endpoint
pertain
quantit
bind
antibodi
titer
mer
cov
spike
glycoprotein
includ
elisa
antibodi
respons
elisa
antibodi
respons
result
present
endpoint
titer
posit
respons
elisa
antibodi
respons
defin
use
specif
threshold
titer
respons
greater
x
dilut
defin
posit
respons
lowest
dilut
test
use
lower
limit
detect
observ
lower
limit
detect
imput
lowest
observ
valu
ie
endpoint
pertain
qualit
quantit
level
neutral
antibodi
mer
cov
defin
use
titer
neutral
antibodi
report
reciproc
highest
dilut
less
cell
show
cytopath
effect
lowest
dilut
test
use
lower
limit
detect
observ
lower
limit
detect
imput
lowest
observ
valu
ie
posit
respons
neutral
antibodi
titer
defin
use
specif
threshold
neutral
antibodi
titer
respons
greater
x
dilut
defin
posit
respons
one
endpoint
pertain
antigenspecif
cellular
immun
respons
mer
cov
determin
interferongamma
elispot
elispot
deriv
subtract
averag
number
spot
form
unit
sfu
count
media
control
well
averag
individu
mer
cov
peptid
well
adjust
pbmc
mer
cov
peptid
pool
obtain
valu
pbmc
thaw
plate
cellswel
cell
incub
mer
cov
peptid
incub
overnight
releas
detect
use
standard
procedur
media
control
well
valu
greater
mer
cov
peptid
well
valu
imput
valu
half
smallest
posit
adjust
valu
use
analysi
valu
mer
cov
peptid
well
tabul
numer
count
tntc
largest
mer
cov
peptid
well
valu
imput
endpoint
pertain
antigenspecif
cellular
immun
respons
mer
cov
determin
ic
cytotox
lymphocyt
phenotyp
lytic
granul
load
granzym
b
kill
target
cell
phase
openlabel
dose
rang
studi
evalu
safeti
toler
immunogen
contain
plasmid
encod
consensu
sequenc
spike
protein
middl
eastern
respiratori
syndrom
coronaviru
mer
cov
current
approv
treatment
prophylact
vaccin
mer
cov
although
number
product
pois
advanc
human
trial
clinic
trial
evalu
whether
administ
via
intramuscular
im
inject
follow
electropor
ep
abl
gener
protect
immun
mer
cov
whether
immun
reactiv
follow
pattern
vaccin
dose
respons
inject
given
deltoid
later
quadricep
muscl
follow
immedi
ep
cellectra
devic
healthi
adult
volunt
male
femal
militari
civilian
recruit
noncoerc
mean
wrair
ctc
accord
applic
us
armi
regul
total
particip
age
divid
group
enrol
studi
follow
week
group
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
group
ii
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
group
iii
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
particip
enrol
lowest
dose
group
continu
enrol
week
enrol
start
week
clinic
laboratori
data
first
five
particip
group
review
part
safeti
review
safeti
lab
review
clear
first
five
particip
group
second
dose
level
open
next
five
particip
met
elig
criteria
enrol
group
ii
enrol
group
complet
group
complet
enrol
particip
group
popul
sequenti
first
five
particip
group
reach
one
week
post
vaccin
safeti
lab
review
safeti
assess
clear
group
iii
open
enrol
next
five
particip
enrol
complet
group
afterward
group
review
safeti
lab
conduct
safeti
monitor
committe
consist
studi
pi
medic
monitor
dod
research
monitor
safeti
review
teleconfer
electron
email
enrol
next
dose
level
requir
approv
review
member
irb
provid
summari
statement
safeti
review
safeti
assess
particip
monitor
local
system
advers
event
ae
studi
visit
laboratori
relat
ae
follow
first
second
third
vaccin
inject
site
reaction
one
month
follow
vaccin
immunogen
assess
studi
explor
humor
cell
mediat
immun
respons
blood
sampl
collect
follow
time
b
abl
provid
consent
particip
sign
inform
consent
form
c
abl
will
compli
studi
procedur
women
childbear
potenti
agre
remain
sexual
abstin
use
medic
effect
contracept
oral
contracept
barrier
method
spermicid
etc
partner
steril
enrol
month
follow
last
inject
partner
unabl
induc
pregnanc
e
sexual
activ
men
consid
sexual
fertil
must
agre
use
either
barrier
method
contracept
studi
agre
continu
use
least
month
follow
last
inject
partner
perman
steril
unabl
becom
pregnant
f
normal
screen
ecg
screen
ecg
clinic
signific
find
q
prior
major
surgeri
radiat
therapi
within
week
group
assign
r
preexcit
syndrom
eg
wolffparkinsonwhit
syndrom
presenc
cardiac
pacemak
automat
implant
cardiovert
defibril
aicd
metal
implant
within
cm
plan
site
inject
u
presenc
keloid
scar
format
hypertroph
scar
clinic
signific
medic
condit
plan
site
inject
v
prison
particip
compulsorili
detain
involuntari
incarcer
treatment
either
physic
psychiatr
ill
w
activ
drug
alcohol
use
depend
opinion
investig
would
interfer
adher
studi
requir
assess
immunolog
endpoint
x
tattoo
cover
inject
site
area
ill
condit
opinion
investig
may
affect
safeti
particip
evalu
studi
endpoint
particip
consid
complet
studi
hesh
complet
schedul
studi
treatment
followup
visit
particip
discontinu
studi
time
dose
investig
make
everi
effort
particip
complet
assess
investig
make
everi
effort
schedul
immun
assess
blood
sampl
collect
unless
particip
refus
continu
particip
followup
visit
procedur
complet
indic
follow
last
dose
whether
particip
complet
dose
data
collect
time
withdraw
includ
final
evalu
lab
result
may
pend
time
withdraw
report
likewis
specimen
collect
time
withdraw
includ
blood
collect
storag
use
futur
research
kept
util
outlin
protocol
consent
form
studi
termin
ecrf
complet
reason
withdraw
specifi
reason
discontinu
investig
product
discuss
sponsor
medic
monitor
indic
studi
form
primari
reason
particip
discontinu
dose
withdraw
studi
select
follow
standard
categori
advers
event
advers
reaction
clinic
laboratori
event
occur
medic
judgment
investig
ground
discontinu
best
interest
particip
includ
seriou
nonseri
advers
event
regardless
relat
studi
drug
death
particip
die
withdraw
consent
particip
desir
withdraw
particip
studi
absenc
investigatordetermin
medic
need
withdraw
particip
gave
reason
withdraw
must
record
crf
reason
allow
data
collect
later
studi
relat
procedur
protocol
violat
particip
fail
meet
protocol
entri
criteria
fail
adher
protocol
requir
eg
treatment
noncompli
failur
return
defin
number
visit
violat
discuss
sponsor
medic
monitor
prior
discontinu
either
studi
treatment
studi
withdraw
lost
followup
particip
fail
attend
studi
visit
studi
personnel
unabl
contact
particip
repeat
attempt
includ
letter
sent
certifi
mail
equival
physician
decis
particip
termin
reason
list
physician
care
particip
incarcer
particip
prison
plan
volunt
suspend
studi
visit
incarcer
irb
notifi
period
incarcer
possibl
site
team
coordin
correct
author
ensur
relev
medic
inform
safeti
care
patient
commun
promptli
particip
termin
reason
list
termin
studi
sponsor
investig
product
use
studi
contain
dna
plasmid
encod
protein
mer
cov
product
provid
concentr
approxim
mgml
dilut
mix
site
need
dose
standard
ml
volum
administ
studi
particip
concentr
final
plasmid
vari
base
dosag
administ
solut
steril
water
inject
swfi
therefor
swfi
use
dilut
biolog
product
clinic
site
formul
vaccin
product
ship
manufactur
vgxi
houston
texa
dri
ice
lot
number
vaccin
use
total
particip
divid
group
enrol
studi
estim
approxim
particip
need
screen
fill
desir
enrol
particip
group
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
group
ii
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
group
iii
particip
assign
receiv
administ
mg
dnados
given
ml
im
inject
follow
ep
cellectra
devic
particip
receiv
seri
immun
week
particip
enrol
lowest
dose
group
continu
enrol
week
enrol
start
week
clinic
laboratori
data
first
five
particip
group
review
part
safeti
review
safeti
lab
review
clear
first
five
particip
group
second
dose
level
open
next
five
particip
met
elig
criteria
enrol
group
ii
enrol
group
complet
group
complet
enrol
particip
group
popul
sequenti
first
five
particip
group
reach
one
week
post
vaccin
safeti
lab
review
safeti
assess
clear
group
iii
open
enrol
next
five
particip
enrol
complet
group
afterward
group
safeti
assess
particip
selfevalu
use
record
post
treatment
reaction
local
system
particip
enter
inform
postvaccin
memori
aid
even
dose
day
post
dose
memori
aid
entri
determin
meet
criteria
grade
higher
advers
event
document
advers
event
addit
safeti
assess
includ
unsolicit
advers
event
laboratori
safeti
assess
unsolicit
advers
event
collect
durat
studi
detail
event
collect
either
onsit
visit
via
telephon
laboratori
safeti
assess
collect
screen
week
week
week
laboratori
safeti
assess
clinic
signific
advers
event
enter
current
correl
immun
mer
cov
defin
clear
neutral
antibodi
direct
surfac
spike
glycoprotein
particular
immunolog
focu
receptorbind
domain
subunit
howev
addit
target
humor
cellular
immun
still
defin
thu
immunogen
assess
measur
known
correl
neutral
antibodi
evalu
potenti
mechan
immun
respons
well
blood
specimen
collect
wrair
ctc
process
us
militari
hiv
research
program
mhrp
laboratori
dr
mark
manak
dr
sheila
peel
specimen
analysi
primari
secondari
immunolog
endpoint
ship
specimen
repositori
actg
laboratori
univers
pennsylvania
addit
specimen
exploratori
endpoint
retain
mhrp
serum
specimen
univers
pennsylvania
sent
batch
shipment
laboratori
dr
gari
kobing
nation
microbiolog
laboratori
nml
winnipeg
canada
undergo
elisa
neutral
analysi
secondari
immunogen
endpoint
pbmc
specimen
univers
pennsylvania
sent
batch
shipment
laboratori
dr
david
weiner
wistar
institut
philadelphia
pa
usa
undergo
elispot
ic
analysi
secondari
immunogen
endpoint
divis
labor
laboratori
assay
provid
tabl
specimen
exploratori
endpoint
analysi
retain
upenn
mhrp
repositori
period
year
whole
blood
acd
yellow
top
tube
pbmc
isol
serum
collect
particip
baselin
day
week
formal
power
analysi
applic
studi
descript
statist
use
summar
data
particip
per
treatment
arm
studi
provid
confid
true
incid
sae
sae
observ
treatment
arm
overal
treat
particip
studi
provid
confid
true
incid
sae
sae
observ
continu
variabl
summar
use
follow
descript
statist
n
nonmiss
sampl
size
mean
standard
deviat
median
maximum
minimum
frequenc
percentag
base
nonmiss
sampl
size
observ
level
report
categor
measur
gener
data
list
sort
dose
level
subject
appropri
visit
number
emm
corpor
version
statist
analysi
plan
protocol
wrair
june
within
subject
summari
tabl
structur
column
dose
level
order
group
annot
total
popul
size
relev
tabletreat
includ
miss
observ
interim
analys
perform
immunolog
assay
sampl
week
visit
complet
final
analysi
describ
sap
perform
main
immunolog
assay
complet
main
immunolog
assay
defin
section
tabular
list
subject
visit
observ
exclud
variou
analysi
popul
provid
csr
appendix
modifi
intent
treat
mitt
analysi
includ
particip
receiv
least
one
studi
treatment
administr
im
inject
ep
particip
sampl
group
base
dose
assign
analys
mitt
sampl
consid
support
correspond
pp
analys
perprotocol
pp
analysi
compris
particip
receiv
treatment
administr
major
protocol
deviat
primari
endpoint
data
avail
particip
defin
primari
endpoint
data
avail
termin
protocol
earlier
activ
treatment
administr
period
activ
treatment
administr
period
defin
prior
week
would
ensur
particip
termin
prior
third
treatment
administr
particip
sampl
group
purpos
tabl
figur
list
base
dose
assign
safeti
analysi
set
includ
particip
receiv
least
one
studi
treatment
postdos
safeti
data
avail
particip
consid
postdos
safeti
data
avail
hesh
attend
least
one
post
treatment
studi
visit
particip
analyz
accord
dose
receiv
protocol
defin
formal
subgroup
analys
studi
adequ
power
perform
subgroup
analys
miss
data
replac
calcul
done
report
valu
interim
analysi
immunogen
data
take
place
week
visit
complet
use
make
decis
concern
conduct
trial
sinc
earli
look
data
intend
impact
conduct
trial
alphaspend
adjust
need
control
overal
type
error
tabl
figur
list
includ
interim
analys
indic
superscript
appendix
includ
data
includ
week
visit
gener
descript
statist
use
summar
data
pertain
nonimmunolog
endpoint
except
safeti
data
analyz
use
fisher
exact
test
ttest
note
section
immunolog
endpoint
analyz
denot
section
adjust
multipl
test
plan
disposit
subject
studi
tabul
group
tabl
appendix
tabl
show
total
number
subject
screen
enrol
receiv
least
dose
receiv
least
dose
discontinu
dose
number
complet
studi
list
subject
discontinu
dose
reason
includ
list
appendix
iii
flowchart
show
disposit
studi
subject
adapt
consort
statement
includ
figur
appendix
ii
figur
present
number
subject
screen
enrol
lost
followup
analyz
group
summari
subjectspecif
protocol
deviat
present
reason
deviat
deviat
categori
treatment
group
subject
immunogen
variabl
list
group
subject
visit
data
summar
group
primari
object
endpoint
summar
section
sinc
pertain
safeti
toler
secondari
object
studi
includ
evalu
cellular
humor
respons
deliv
im
follow
ep
well
evalu
dose
respons
cellular
humor
reactiv
deliv
im
follow
ep
compar
elisa
titer
respons
across
three
group
studi
day
determin
whether
respons
differ
dose
analyz
use
kruskalw
test
test
nonparametr
test
extens
two
group
wilcoxon
rank
sum
test
two
group
sinc
sampl
size
larg
enough
assum
asymptot
normal
analys
endpoint
like
skew
titer
respons
nonparametr
test
employ
requir
distribut
assumpt
null
hypothesi
kruskalw
test
three
differ
dose
group
distribut
elisa
respons
particular
studi
visit
signific
differ
determin
use
kruskalw
test
pairwis
comparison
evalu
ident
statist
analys
compar
neutral
antibodi
titer
respons
across
three
group
studi
day
note
elisa
endpoint
use
describ
immunolog
endpoint
summar
graphic
display
trend
time
differ
dose
group
comparison
trend
allow
qualit
assess
exploratori
endpoint
includ
comparison
bind
antibodi
mer
cov
neutral
antibodi
titer
kinet
durabl
bind
antibodi
mer
cov
neutral
antibodi
titer
comparison
elispot
ic
respons
across
differ
vaccin
dose
kinet
durabl
elispot
ic
respons
across
differ
vaccin
dose
primari
object
studi
evalu
safeti
toler
administ
im
inject
follow
ep
healthi
adult
particip
safeti
assess
includ
primari
safeti
endpoint
defin
follow
subsect
safeti
outcom
assess
dose
group
order
lowest
highest
mgdose
mgdose
mgdose
overal
includ
dose
group
demograph
baselin
data
vital
sign
medic
histori
concomit
ill
current
medicationstreat
summar
mean
descript
statist
mean
standard
deviat
minimum
median
maximum
valu
continu
variabl
percentag
categor
variabl
stratifi
treatment
group
analysi
modifi
intenttotreat
analysi
individu
screen
enrol
contribut
data
henc
exclud
summari
age
baselin
temperatur
baselin
respir
rate
baselin
blood
pressur
baselin
heart
rate
gender
ethnic
race
present
group
tabl
appendix
ethnic
categor
hispan
latino
hispan
latino
accord
nih
report
polici
subject
may
selfdesign
belong
one
race
may
refus
identifi
race
latter
reflect
crf
racial
option
current
ill
past
preexist
medic
condit
meddra
code
use
meddra
dictionari
version
higher
summari
subject
preexist
medic
condit
present
group
tabl
appendix
individu
subject
list
present
medic
condit
list
appendix
iii
subject
receiv
three
treatment
administr
clinic
number
treatment
administr
subject
present
treatment
group
site
part
subject
disposit
tabl
tabl
appendix
addit
list
treatment
administr
complianc
data
provid
list
appendix
iii
includ
whether
refluxleakag
occur
inject
site
administr
calcul
incid
advers
event
ie
per
subject
basi
subject
count
repetit
advers
event
within
subject
ignor
denomin
total
number
subject
advers
event
report
includ
summari
analys
one
primari
endpoint
interest
administr
inject
site
reaction
local
solicit
event
pertain
administr
inject
site
reaction
includ
tender
pruritu
erythema
indurationswel
bruis
system
solicit
event
includ
fever
malaisefatigu
myalgia
headach
arthalgia
nausea
local
system
event
record
tabl
summar
proport
subject
report
least
one
solicit
advers
event
summar
solicit
advers
event
system
symptom
local
symptom
symptom
ci
calcul
use
clopperpearson
methodolog
binomi
distribut
sa
proc
freq
binomi
option
present
fisher
exact
test
perform
test
differ
proport
subject
report
solicit
advers
event
tabl
appendix
unsolicit
ae
summar
day
period
follow
administr
studi
treatment
proport
subject
report
least
one
unsolicit
advers
event
summar
meddra
system
organ
class
prefer
term
vaccin
vaccin
denomin
percentag
number
subject
receiv
vaccin
summar
ci
present
along
fisher
exact
test
compar
treatment
group
test
differ
proport
subject
report
unsolicit
advers
event
meddra
system
organ
class
prefer
term
advers
event
subject
present
list
appendix
iii
follow
summari
unsolicit
advers
event
present
meddra
system
organ
class
prefer
term
dose
group
subject
level
summari
tabl
frequenc
incid
nonseri
advers
event
display
bar
chart
sever
meddra
system
organ
class
group
figur
appendix
ii
respect
overal
frequenc
incid
advers
event
sever
group
display
figur
respect
frequenc
incid
nonseri
advers
event
display
bar
chart
relationship
treatment
meddra
system
organ
class
group
figur
appendix
ii
respect
overal
frequenc
incid
advers
event
relationship
treatment
group
display
figur
respect
report
period
sae
without
regard
causal
entir
period
follow
sign
inform
consent
form
end
studi
subject
safeti
popul
becam
pregnant
pregnanc
partner
male
particip
expos
studi
treatment
studi
everi
attempt
made
follow
subject
complet
pregnanc
document
outcom
includ
inform
regard
complic
pregnanc
andor
deliveri
list
pregnanc
outcom
present
list
appendix
iii
descript
statist
includ
mean
standard
deviat
median
minimum
maximum
valu
studi
day
laboratori
paramet
summar
tabl
appendix
chang
laboratori
valu
present
figur
appendix
ii
vital
sign
measur
includ
oral
temperatur
respir
rate
blood
pressur
heart
rate
measur
specifi
visit
baselin
vital
sign
summar
medic
taken
medic
procedur
perform
within
week
prior
enrol
studi
must
record
case
report
form
bysubject
list
concomit
medic
use
present
list
appendix
iii
ecg
perform
screen
particip
determin
elig
ecg
includ
measur
ventricular
rate
pr
qr
qt
qtc
assess
whether
ecg
normal
abnorm
abnorm
ecg
interpret
clinic
signific
clinic
signific
dose
delay
event
clinic
signific
abnorm
predos
ecg
review
pi
qualifi
pi
designe
medic
monitor
sponsor
consult
cardiologist
deem
safe
proceed
pvalu
report
decim
place
pvalu
less
report
pvalu
greater
report
mean
standard
deviat
statist
quantil
report
one
decim
place
greater
origin
data
quantil
median
minimum
maximum
use
number
decim
place
origin
data
proport
present
two
decim
place
valu
present
percentag
report
nearest
whole
number
valu
present
estim
paramet
scale
raw
observ
eg
regress
coeffici
report
signific
figur
sa
version
use
gener
tabl
figur
list
protocol
refer
summar
current
medicationstreat
via
descript
statist
rather
descript
statist
current
medic
summar
via
line
list
week
week
week
week
week
week
week
week
week
n
number
subject
mitt
popul
day
x
xx
xxx
xx
xx
xx
xx
xxx
xx
xx
xx
xx
xxx
xx
xx
xx
xx
xxx
xx
xx
xx
xx
xx
week
week
week
week
week
week
week
week
week
week
protocol
wrair
june
statist
analysi
plan
appendix
week
week
week
week
week
week
week
week
week
week
protocol
wrair
june
statist
analysi
plan
appendix
